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Abstract
The evolution of drug resistance in human immunodeciency virus (HIV) infection has
been a focus of research in many elds, as it continues to pose a problem to disease
prevention and HIV patient management. In addition to techniques of molecular
biology, studies in mathematical modelling have contributed to the knowledge here,
but many questions remain unanswered. This thesis explores the application of a
number of hybrid stochastic/deterministic models of viral replication to scenarios
where viral evolution may be clinically or epidemiologically important. The choice of
appropriate measures of viral evolution/diversity is non-trivial, and this impacts on
the choice of mathematical techniques deployed. The use of probability generating
functions to describe mutations occurring during early infection scenarios suggest
that very early interventions such as pre-exposure prophylaxis (PrEP) or vaccines
may substantially reduce viral diversity in cases of breakthrough infection. A modied
survival analysis coupled to a deterministic model of viral replication during transient
and chronic treatment helps identify clinically measurable indicators of the time it
takes for deleterious rare mutations to appear. Lastly, persistence of problematic
mutations is studied through the use of deterministic models with stochastic averaging
over initial conditions.
ix
Acknowledgements
I would like to thank Dr Alex Welte, my supervisor, for his guidance, mentorship,
many suggestions and constant support during this research. I am also thankful to
Nina Feerman for introducing me to the research eld of social networks and her
guidance throughout the year (March 2009 - March 2010) whilst visiting DIMACS at
Rutgers University.
The SACEMA bursary, which was awarded to me for the period 2007{2010, was
very crucial to the successful completion of this project. I would also like to thank
Professor Fred Roberts for the DIMACS research fellowship at Rutgers University,
and the useful contacts and friendly encouragement that he gave me.
I had the pleasure of meeting David Wick and his fellow SCHARP sta members
in Seattle. They are wonderful people. Dave's invitation and advice made me enjoy
my research and I would also like to thank him for the reading material (books and
preprints). We also had stimulating discussions on modelling methods.
Of course, I am grateful to my wife and my parents for their patience and love.
Without them my stay in South Africa would have been a nightmare (literally).
Thank you for the calls every night, those made me keep going and proud to have
such a loving family.
Finally, I wish to thank the following: Peter Olofsson and Marek Kimmel (for
their technical assistance on branching processes); Alantha Newman (for stimulating
discussions); Levin Lab Tea (for the stimulating talks in ecology and evolutionary
biology) and Feerman Lab members (for all the good times we had together). I
might have forgotten the people who were involved in the early stages of my studies,
my apologies to all those.
x
Chapter 1
Introduction
1.1 Background
In this chapter, we furnish the reader with current facts on the impact of HIV (Human
Immunodeciency Virus)/AIDS (Acquired Immune Deciency Syndrome) disease and
HIV pathogenesis. We also give a little essay about the general situation in modelling
viral genetics, important modelling work in HIV evolution, what has been achieved
so far in the eld of HIV modelling and highlight questions that remain unanswered.
The Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World
Health Organization (WHO) 2009 [143] estimated that by December 2008, nearly 34.4
million individuals were living with the disease, the virus killed 2 million people and
2.7 million individuals were infected in 2008. Again, sub-Saharan Africa is still leading
on the number of people living with the disease (22.4 million) and the epidemic is still
the leading cause of death (1.44 million deaths in 2008) in sub-Saharan Africa [133].
The epidemic's eects are multi-faceted, aecting not only an individual's health but
also impacting life style, the structure of families and society. This disproportionate
burden of the global pandemic threatens sub-Saharan Africa's economic and social
fabric.
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2Currently, science has produced no magic bullet, there is still no cure and vaccine
although recently there were reports of a vaccine with some ecacy [124] and a modest
ecacy aorded by 1% Tenofovir vaginal gel [70]. Given the ongoing burden of the
HIV pandemic, new proposals for controlling the epidemic now include circumcising
men [7], giving a daily prophylactic pill to high risk groups [121], and testing and
treating as many infected individuals as countries can aord to reduce transmission
[50]. These, together with the traditional prevention methods such as abstinence,
faithfulness, use of condoms and treatment, form a comprehensive prevention package.
Although signicant progress has been made in reducing new infections in some
contexts and in prolonging individual lives, there are still challenges. Mechanisms of
HIV disease progression are still unclear and there is still no convincing explanation
why there is a long and variable asymptomatic phase. Some infected individuals have
died within one or two years of infection, while others are still asymptomatic after 15
years [48, 94, 110]. The rapid accumulation of mutations in HIV, the theme of this
thesis, presents a great challenge to treatment and therapeutic development eorts.
Understanding key evolutionary and ecological processes underlying successful viral
lineages, the timing of key events in viral emergence is relevant to vaccine design and
other control eorts.
1.2 HIV Pathogenesis
HIV is a complex virus that belongs to the lentivirus (because it causes disease slowly)
genus of the retroviridae family [76], which `reversely' transcribe their ribonucleic
acid (RNA) genome to deoxyribonucleic acid (DNA). Other examples of retroviruses
are simian immunodeciency viruses (SIV) that mainly infect sooty mangabeys and
3rhesus macaques [82]. The virus encodes major precursor polypeptides and several
accessory genes which are indispensable to its life cycle. As a retrovirus, HIV does
not have the required mechanisms to prevent errors during the transcription process,
and therefore it is prone to generating a large number of copying errors.
After infection, HIV leads to primary infection where there is high viral load and
massive dissemination of the virus throughout the body. Subsequently, infected indi-
viduals enter an asymptomatic phase that can last for years. The hallmark of HIV-1
infection is the depletion and incapacitation of immune cells central to human antimi-
crobial defenses. The depletion of the CD4+ T cells with no medical intervention may
result in a situation where the viral population ourishes, leading to a state where the
immune system becomes heavily compromised in ghting o opportunistic infections,
known as the AIDS stage [133]. Initiation of eective antiretroviral therapy results in
a decay in plasma HIV-1 RNA levels and a concurrent increase in the CD4+ T cell
count [62].
Currently, the use of antiviral therapies in HIV-1 infected individuals has signi-
cantly impacted on HIV/AIDS morbidity and mortality and this has greatly improved
the prognosis of people living with the virus [118]. Clinical and immunologic stabil-
ity are the favourable outcomes of antiretroviral treatment. Management of HIV-1
infected patients has become increasingly complex due to expanding choices of drug
regimens, emergence of resistance and drug tolerability problems. With the increase
in numbers of patients receiving antiviral therapy, concerns about the long term man-
agement of patients and resources are being explored on multiple fronts, from training
and logistics, to mathematical modelling. It is clear that a novel portfolio of HIV-1
prevention ideas is required.
41.3 The Evolution of HIV
The techniques of modern molecular biology have elucidated many aspects of HIV-1
infection, and some ne details about the immune responses mounted by the host to
ght infection [8, 19, 90, 93, 103]. To complement this knowledge, mathematical tech-
niques may be used to facilitate the analysis and interpretation of dynamic processes
such as viral transmission, multiple viral evolutions within the host and the interplay
between viral population growth and drugs/immunological responses. Mathematical
techniques allow the description of biological systems in terms of hazards or rates of
the processes. Mathematical modelling of the dynamics of HIV-1 infection within an
individual has become a substantial area of research. Genuine advances have been
modest in number, but large in impact.
Historically, there have been three primary approaches to thinking about in-vivo
viral evolution: population genetics, ecological genetics, and quasispecies (for a more
complete review see Wick et al.[150]). Population genetics began with R. A. Fisher in
his 1930s book [38]. In his thinking he included rivals (members of the same species)
but not enemies (members of other species which act as predators or parasites). It was
a conscious decision to leave ecology to others. This xes the demographic popula-
tion size, imagining that there are a particular number of niches; population dynamics
became simply reproduction followed by random sampling, with the `selection coef-
cient', or tness of each sub-species determining the probability an ospring gets
a niche, i.e. competition so strong that if one subspecies population goes up by x,
another must decline by x. Under these assumptions, Fisher proved his Fundamental
Theorem of Natural Selection: average tness in every population always increases.
E. B. Ford invented the eld of ecological genetics [40]. He investigated the role
5of natural selection in nature by studying British birds and moths; the moths varied
the spots on their wings to avoid predation by birds. Ford considered that ecological
genetics dealt with adjustments and adaptations of wild populations to their natural
environment. Characteristic of ecological genetics is that organism traits are related
to tness, which aect an organism's tness.
Quasispecies were introduced by Eigen and Schuster in the 1970s [33, 34]. A
quasispecies is a group of related genotypes that exist due to high mutation rates.
The quasi-species model is a description of evolution of certain self-replicating entities
within the framework of physical chemistry. They discovered the high mutation rate in
RNA viruses and modelled populations using ordinary dierential equations (ODEs).
Deterministic approaches, mainly using ODEs, have been the core of most ecolog-
ical models, including virus population dynamics. Simple ODEs have been solved to
t to sets of observational HIV-1 RNA viral load data [62, 120] in order to estimate
the parameters of viral and cellular kinetics. Signicant insights into HIV-1 dynamics
such as rates of viral turnover and virus clearance rates have been derived from the
basic model of HIV-1 dynamics [115, 120, 145]. However, the basic model is simplistic
in that it only describes a single strain, whereas in reality there are many coexisting
strains.
It has been widely adopted and modied to model plasma viral load in HIV-1
infected patients, for example see [13, 105, 108, 113, 144]. Some of these models
have been used to estimate viral growth rates, basic reproductive numbers and post
peak decay rates [87, 114, 128]. Other extended versions of the basic model have
been used to explore the evolution of drug resistant mutants [42, 98, 111, 115, 126,
127, 136, 144]. Nowak et al. explored the evolutionary mechanism for HIV disease
6progression [111] and the eect of treatment in reducing viral diversity [116]. In
another study, Wahl and Nowak [144] used modelling to assess the conditions under
which resistance dominates as a result of imperfect adherence. Wodarz and Lloyd
[152] also investigated the role of immune responses in emergency of drug resistant
mutants.
ODEs are both elegant and powerful, but there are instances when they miss
relevant aspects, as will be illustrated in chapter 2. Monte Carlo simulations of
within host HIV dynamics have also been used as alternatives to ordinary dierential
equations [61, 106, 131, 139, 142]. Wick and Self have used compartmental Markov
models to explore whether cytotoxic T lymphocytes (CTLs) really control HIV in-
fection [147, 148] and assess the inuence that the timing of immune responses and
drugs have on the rate of disease progression [146]. Recently, a stochastic spatial
model based on the Monte Carlo approach was developed to study the dynamics of
HIV infection, and it successfully reproduced the three-phase pattern observed in HIV
infection [83].
Recent advances through coupling data analysis and mathematical modelling have
allowed the identication and characterization of the nature of the transmitted virus
[71]. Monte Carlo methods have been used to capture the stochasticity of early
infection focusing on sequence evolution of the virus [79]. These models of random
mutations have been used successfully to assess viral diversity as an indicator of
the number of transmission events or founder strains [71, 79] and also to simulate the
eects of mutations and tness on the correlation between HIV quasispecies evolution
and disease progression [80].
71.4 Structure of the Thesis
The overall objective of this thesis is to test and develop appropriate methods for
modelling the eects of immune system pressure and therapeutic intervention on virus
diversication. We then use these models to investigate the impact of acute infection
dynamics on the accumulation of mutations, the eect of suboptimal therapy on the
appearance of rare higher order mutations (those that do not typically exist at most
points in time) and the persistence of these new genomes.
In chapter 21, we give a critical review of some of the modelling techniques that
have been used to explore virus evolution. We also compare various indicators of viral
diversity and show how they impact on the choice of mathematical techniques.
Chapter 32 explores how the dynamics of early infection aects the accumula-
tion of mutations which lay the seeds for long term evolution of drug resistance and
immune system evasion, using a branching process model in a deterministically vary-
ing environment. We relate applications of these ideas to pre-exposure prophylaxis
(PrEP) and vaccine strategies.
We present a strain-dierentiated hybrid deterministic-stochastic population dy-
namic type model of healthy and infected cells in chapter 43 to explore how the tran-
sient increase in a population of cells transcribed with a common mutation, which
occurs in response to a short course of monotherapy and chronic treatment, has an
impact on the risk of appearance of rarer, higher-order, therapy-defeating mutations.
In chapter 54,we analyze the full hybrid model. The objective is to explore
1Part of the content was presented as a poster at: DIMACS Capstone Workshop on Mathematical
Modelling of Infectious Diseases in Africa (25-27 June 2007)
2Published in J. Theor. Biol. 2011; 279(1): 44-54
3Most of the content was published in Theor. Biol. Med. Model. 2008; 5: 25
4Manuscript in Preparation
8how long specic viral variants persist in the population, if suboptimal treatment
is stopped. Finally, in chapter 6, we take stock of what was achieved in the thesis
and suggest direction for future work.
Chapter 2
Review of Modelling Techniques
Introduction
The thesis is about how to construct and apply appropriate mechanistic models of in-
vivo viral replication. We now give a review of some of the modelling techniques that
have been used for viral dynamics. At a high level, we distinguish deterministic models
from stochastic models, and note that they can be formulated in either continuous or
discrete time. In each case, the dening elements are state variables and dynamical
rules, but we also pay attention to `metrics' of viral diversity that can be computed
from the model ingredients.
2.1 Continuous Time Models
A large variety of in-vivo HIV models are based on continuous time processes, as these
are often analytically tractable (closed form solution or ecient numerical schemes).
Examples of these models are in the form of ODEs, stochastic dierential equations
(SDEs) and partial dierential equations (PDEs). Of these models, ODEs have been
9
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at the core in modelling the complex set of interacting concepts that are relevant to
the dynamical understanding of HIV evolution. In the setting of HIV, which replicates
very fast, some mutations, such as known single base mutations, cannot be avoided.
They are repeatedly generated even though they might be kinetically compromised.
By contrast, in a given patient/environmental context, there may be rare mutations
which are unlikely to occur during an infected individual's lifetime. ODE models are
appropriate to investigate the evolution of common mutants and are not appropriate
to model rare events. In the following section, we demonstrate that ODEs fail to
capture correctly the dynamics of rare mutations. For example, mutants which will
almost certainly not happen in a stochastic model are instantaneously generated as
innitesimal populations in an ODE model. In reality, a new rare mutant shows up
in a single productively infected cell, while continuous models such as ODEs produce
innitesimal population sizes which immediately become a dynamical entity without
a waiting time.
Modelling Rare Mutation Events
The rate of evolution of HIV in-vivo is probably greater than for any other persistent
infection, for example, the mutation rate per nucleotide per round of replication
is about 3  10 5 [92]. This is very high considering that for eukaryotes is closer
to 10 10 [77]. The number of productively infected cells is around 108 in chronic
infection; therefore, every mutation in HIV's genome which is about 104 nucleotides
is made everyday [24, 55]. We are interested in the dynamics of quasispecies, therefore
we mainly consider dierent types of infected cells which will be denoted by Pi; i.e.
which distinguishes cells infected by strain i: These dierent cell types reproduce at
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dierent rates. Right now, we present a basic model of virus dynamics [115, 120] with
a single strain labeled P1: The single strain ODE model is given by
dT (t)
dt
= ST   k1T (t)P1(t)  TT (t);
dP1(t)
dt
= fk1P1(t)T (t)  PP1(t); (2.1.1)
where ST is the rate at which healthy or target cells T are generated, k1 is the wild-
type strain infectivity parameter, T is the natural target cell death rate, P is the rate
at which infected cells are cleared, and f is the probability of error free transcription.
The model (2.1.1) does not explicitly include the virus population. The free virion
decay rate is much larger than the decay rate of virus-producing cell populations. By
standard analysis of the separation of fast and slow dynamics, one shows that to
a good approximation, the free virus population is in a quasi equilibrium with the
lower mortality cell population, according to the relation V1(t) = P1(t); where the
constant  contains virion production rates and mortality. Thus, the dynamics of a
model with virions can be reproduced by system (2.1.1) unless one is asking questions
about very short time scales, i.e. short compared to the mean lifetime of a virion,
which we do not do. Incorporating virions in our model can help distinguish how
certain drugs work, for example, reverse transcriptase inhibitors (RTIs) that block
reverse transcription early in infection cycle and protease inhibitors (PIs) that block
viral maturation at the end of the virus life cycle. To distinguish the dynamics of
these drugs clinically requires high quality HIV RNA data that may be separated by
hours which means frequent blood drawing from patients.
The ODE model has a disease free equilibrium given by
T 0; P 01

=

ST
T
; 0

(2.1.2)
12
and an infected equilibrium state given by
T ; P 1

=

P
fk1
;
T
k1
(R0   1)

; (2.1.3)
where R0 is the basic reproductive number (which can be thought as the number of
new infections caused by one infection in an extremely susceptible population, i.e. at
the beginning of infection [4]) given by
R0 =
fSTk1
PT
:
Theorem 2.1.1. If R0 > 1, then the infected equilibrium state (equation 2.1.3) is
locally asymptotically stable.
Proof. We investigate local stability by evaluating the linearized system at the in-
fected equilibrium state. This equilibrium state is locally asymptotically stable if and
only if all the eigenvalues of the Jacobian matrix J have a strictly negative real part.
We determine the eigenvalues by solving the characteristic equation of the Jacobian
matrix J given by
J

T ; P 1

=
0B@  TR0  Pf
fT(R0   1) 0
1CA : (2.1.4)
The characteristic equation is given by
2 + TR0+ PT(R0   1) = 0; (2.1.5)
such that the two eigenvalues are given by
1;2 =
 TR0 
p
(TR0)2   4PT(R0   1)
2
: (2.1.6)
Using the Routh-Hurwith stability criterion [49] we conclude the existence of roots
with negative real parts if and only if R0 > 1:
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In the setting of HIV infection, some common variants are created quickly early
after infection with a single founder strain. This model can be extended to accommo-
date a new variant that can emerge, say mutant P2. The new model that describes
the dynamics of two strains is given as:
dT (t)
dt
= ST   k1T (t)P1(t)  k2T (t)P2(t)  TT (t);
dP1(t)
dt
= fk1P1(t)T (t) + k2P2(t)T (t)  PP1(t); (2.1.7)
dP2(t)
dt
= fk2P2(t)T (t) + k1P1(t)T (t)  PP2(t);
where  is the mutation rate and k2 is the new mutant strain infectivity parameter.
In this model, the wild-type strain P1 is the initially infecting strain and the mutant
strain P2 is a result of mutations from the wild-type strain. Similarly, the two-strain
deterministic model has two steady states: the uninfected steady state and a unique
infected steady state which is either physical (a positive number of infected cells) or
unphysical (a negative number of infected cells) depending on the tness parameters.
The uninfected steady state is given by

T 0; P 01 ; P
0
2

=

ST
T
; 0; 0

: (2.1.8)
The exact infected steady state is given by
T =
P

f(k1 + k2) 
p
f 2(k1 + k2)2   4(f 2   2)k1k2

2(f 2   2)k1k2 ;
P1 =
 
ST   T T
 
P   fk2 T

k1 T
 
P   (f   )k2 T
 ; (2.1.9)
P2 =
k1 P1 T
P   fk2 T :
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For a high value of the mutation production rate k1P1T; i.e. for very small intervals
between individual mutation events, mutant infected cells are quickly generated, thus
we can call P2 a common mutant. This model is sensible to capture the dynamics of
common mutants, where the appearance of a new variant is captured by the parameter
 and its growth is captured by parameter k2: For small values of k1P1T; in reality
the mutant might never occur, thus we call it a rare mutant. Here, we need to check
whether it makes sense to model the appearance of rare mutations as a deterministic
process, as was done by some of the authors including [115, 116, 136].
Now, we consider P2 as a tter rare mutant which may arise when healthy and
wild-type infected cells are at equilibrium (infected steady state, equation 2.1.3). As
an approximation, we assume that this mutant population grows exponentially during
the initial stages such that its dynamics are given by a linear ODE
dP2(t)
dt
= P (   1)P2(t) + sT

R0   1
R0

; (2.1.10)
where  = k2=k1 > 1: We have also assumed that healthy and wild-type infected
cell populations are not signicantly perturbed from their initial values (i.e. from
the infected steady state) over the time it takes to produce one cell of the tter rare
mutant. Solving the equation P2(t) = 1 for t; we have the evolutionary time required
to have one cell infected by an advantageous mutant strain in the population, i.e.
t1 =
1
P(   1)ln

1 +
P(   1)R0
ST(R0   1)

: (2.1.11)
On the other hand, the stochastic mean waiting time before the appearance of a
mutant is given by
< tw > =

1
k1P 1 T 

;
=
R0
ST(R0   1) : (2.1.12)
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We numerically integrate the evolution of wild-type and mutant strain infected cells
using the fourth order Runge-Kutta scheme when:
1. there is no waiting time for dierent values of  in gure 2.1 and
2. there is a mean waiting time of 186 days calculated from equation 2.1.12 using
the chosen parameters in gure 2.2 and gure 2.3.
Figure 2.1 and Table 2.1 show that the evolutionary time depends on the mutant
infectivity parameter and the mutation rate in the deterministic framework.
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Figure 2.1: Growth of mutant strain with no waiting time. The other parameter
values are R0 = 148; ST = 2 108; P = 0:5; k1 = 2 10 8 and  = 2:7 10 11: The
initial values for the healthy T cells and the wild-type strain are given by equation
2.1.3 and that of the rare mutant is zero.
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Figure 2.2: Growth of mutant strain including a mean waiting time of 186 days. The
other parameter values are as in gure 2.1
We use equations 2.1.11 and 2.1.12 to generate values in Table 2.1.
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Figure 2.3: Growth of mutant strain including pseudo sampled waiting times. The
times (< tw >) chosen are 42, 95, 172 and 300 which are chosen so that there are
spaced inversely proportional to the probability density. The other parameter values
are as in gure 2.1 and k2 = 1:5k1:
The appearance of a rare mutation will almost certainly not happen in an individ-
ual's lifespan, for example numbers in brackets for < tw > in Table 2.1 as calculated
from a stochastic model. In an ODE framework, there is an instantaneous creation of
innitesimal populations (from the mutation term) and the dynamic property (given
by the infectivity parameter) of the strain will drive the growth such that there is
a signicant population size within days (see numbers in brackets for t1 calculated
from a deterministic model). In reality, the mean waiting time for the emergence of
a mutant strain depends on the mutation rate and not on the selective advantage or
disadvantage of the mutant.
In chapter 4, we use a combination of ODE and stochastic models to calculate the
probability of appearance of rare mutations. We use concepts of survival analysis,
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Table 2.1: Deterministic times (in days) to generate a single three-point mutant (t1)
and stochastic mean waiting times before the appearance of a mutant (< tw >), for
dierent values of R0;  = k2=k1 > 1 and  = 2:7 10 11: The gures in brackets are
obtained when  = 2:7 10 14:
R0 < tw > t1
 = 2  = 1:5  = 1:05
2 370 [370370] 10 [24] 18 [46] 93 [365]
10 206 [205760] 9 [23] 16 [43] 73 [342]
148 186 [186440] 9 [23] 16 [43] 69 [338]
i.e. we introduce mutations at random, as a state-dependent Poisson process. Within
this framework, we use the conventional survival analysis to ask questions such as
how long till a key event occurs or the probability that an event has not occurred.
We then use a modied survival analysis to calculate the probability that the key
event has not `occurred recently'.
Furthermore, it is important not just for the rare mutant to appear in one produc-
tively infected cell, but for its lineage not to go extinct. However, the modied survival
analysis framework does not allow us to investigate in a dynamically consistent way
whether the new cell harboring the rare mutant will die before infecting other cells
or before infecting enough other cells for the mutant to be xed, i.e. the persistence
of the new mutants. We run full simulations of the hybrid deterministic-stochastic
model in chapter 5 to investigate persistence of new variants with a subcritical t-
ness. The new rare mutant has to compete with existing strains and its persistence
depends on its characteristics such as viability and replication ability. Varying the
new genome's replicative ability, we determine the period at which the new genome
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lineage will be sustained in the face of competition from existing strains after the
initial appearance of a single cell with a new genome.
2.2 Discrete Time Models
Mathematical biology is about modelling discrete populations, e.g. cells, usually
changing over time. Continuous time models in the form of ODEs formally enforce
that, in any time interval, actual population change equals the expected change of that
population as it would be conceived in some stochastic model. While a deterministic
model (formulated in either continuous or discrete time) predicts a single outcome
for a given set of parameters, a stochastic model predicts a set of possible outcomes
weighed by their likelihoods or probabilities. There are many types of deterministic
and stochastic discrete models. Examples of stochastic discrete models include birth
and death models, Markov models and branching processes. We compute important
indicators of viral diversity using a branching process model of viral evolution.
The model folds in the notions of the mutation rate, reproductive ratio and gen-
eration time (implemented as discrete non-overlapping generations). The branching
process model is as follows: one infected cell initiates the process. On replication,
each cell produces a deterministic number of new cells (say R0); the type of each new
daughter cell may or may not be the same as that of the parent cell, i.e. infected
cell populations evolve as a stochastic process with random choices for the type of
ospring. This model assumes exponential viral growth with no selection pressure, no
recombination and a constant mutation rate across sites and lineages. We consider two
fundamentally similar approaches to calculate viral diversity properties. In the rst
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framework, we explicitly calculate diversity properties for each evolving individual
species (simulation based computational approach - at every time point population
sizes are updated). The second framework involves calculating statistical properties
of ensembles (mean elds) using the theory of probability generating functions. Mod-
els of random mutations have been used successfully to assess viral diversity as an
indicator of the number of transmission events or founder strains [71, 79].
Simulation Based Computational Approach
In this framework, proposed by Lee et al. [79], we consider infected cells carrying
a genome of length NB; i.e. a sequence of nucleotides A, T, C, and G. Mutations
can occur in any of the NB sites in the entire genome. At the rst replication cycle,
the R0 daughter cells produced by the single infected cell will each dier from the
infecting strain at exactly m positions with probability given by
P(mutations = m) =

NB
m

m

1  
NB m
;
where  is a per base mutation rate. The authors [79] showed that the total number
of mutations after n replication cycles (assuming that no back mutations), will follow
the probability distribution
P(mutations = mjgen = n) =

nNB
m

m

1  
nNB m
;
a convolution of n binomial distributions which is also a binomial distribution. The
Hamming distance (HD0) is dened as the number of base dierences from the
founder strain, assumed to coincide with the number of mutations and therefore
it follows the same distribution:
P(HD0 = djgen = n) =

nNB
d

d

1  
nNB d
: (2.2.1)
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In addition to comparing any given sequence to its founder, all sequence pairs in a
sample can be used to calculate their relative Hamming distance, where the distribu-
tion of the intersequence Hamming distance (HDI) distribution is
P(HDI = djgen = n) =

2nNB
d

d

1  
2nNB d
: (2.2.2)
Based on the calculated Hamming distance from the founder strain and the interse-
quence Hamming distance between all possible sequence pairs, the authors dened
the following measures of diversity at any generation n :
1. Divergence as the average Hamming distance per base from the founder strain
and using equation 2.2.1, it can be estimated as the mean of the binomial
distribution divided by the number of bases, i.e. n:
2. Diversity as the average intersequence Hamming distance per base between
sequence pairs and by using equation 2.2.2 is given by 2n:
3. Sequence identity as the proportion of sequences identical to the founder strain
sequence, using equation 2.2.1 and setting d to zero, we have (1  )nNB :
4. Expected maximum Hamming distance, see [79]
All these four measures of diversity depend only on the number of generations and
the authors [79] argued that the number of transcriptional events that have occurred
along a lineage are important in determining viral diversity and not the number of
cells infected at each generation. Monte Carlo based simulations can be used to
calculate the dened indicators of viral diversity.
The simulation starts at generation zero with one infected cell with a single HIV-
1 sequence NB bases long. The founder sequence is generated randomly with base
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frequencies for [A C G T] given by [0.373 0.193 0.241 0.192]. At every generation
each infected cell infects R0 other cells synchronously. Mutations occur during in-
fection and the occurrence of the base substitutions are chosen randomly from NB
bases. The probability that base i is replaced by base j is given by a 4 4 transition
matrix deduced from a simple parametric model of nucleotide substitution by Jukes
and Cantor [69], i.e. all nucleotides are equally likely to undergo substitution and
given that a substitution has taken place, any other nucleotide is equally likely to
be a replacing nucleotide (uniform replacement). Lee et al. [79] used the maximum
likelihood General Time Reversible (GTR) model of substitutions. At each genera-
tion exactly Ns sequences are sampled with replacement and the Hamming distance
distribution is constructed. Multiple runs are performed with Hamming distance
frequencies computed at each generation step averaged over all iterations giving the
mean eld measures of diversity given by the closed form equations.
We assume a genome with NB = 2600 bases, a base substitution rate of  =
2:16  10 5 per base per replication [79] and R0 of 2. Each run consists of 1000
replicates with the maximum number of generations given by 50. At each generation,
Ns = 30 nucleotide sequences were chosen randomly from the population and are
used to calculate the metrics. When the total population exceeds 104, we allow 104
cells (selected at random from a uniform distribution) to multiply and sample another
104 from 104R0 new cells to contribute to the next generation. The simulated results,
showing the dependance of the metrics of diversity on the number of generations, are
given in gure 2.4 (the simulations match the formulas). The results still coincide
with the ones obtained by Lee et al. [79], when they assumed a GTR model of
substitutions and a reproductive ratio (R0) of 6.
24
0 10 20 30 40 50
0
0.05
0.1
0.15
0.2
generations
Di
ve
rg
en
ce
 (%
)
0 10 20 30 40 50
0
0.05
0.1
0.15
0.2
generations
Di
ve
rs
ity
 (%
)
0 10 20 30 40 50
0
5
10
15
generations
M
ax
im
um
 H
D
0 10 20 30 40 50
0
50
100
generations
Se
qu
en
ce
 Id
en
tity
 (%
)
DC
BA
Figure 2.4: Monte Carlo simulations of the synchronous infection model. Dynamics
of (A) divergence - average hamming distance per base from the founder strain,
(B) diversity - average inter sequence hamming distance per base between sequence
pairs, (C) maximum hamming distance and (D) percentage identity - proportion of
sequences identical to the founder strain, for sequences of length 2600, and from 1000
simulations where n is the generation. The vertical bars are the standard errors.
A Critical Review of The Number of Transmission Events
To expand the analysis of the synchronous model with full viral genome, we allow
multiple infections by distinct types to initiate the infection process. For simplicity, we
assume two very distinct founder sequences with dierent tness values (i.e. dierent
reproductive ratios). The reproductive ratios of the two founder strains are R01 and
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R02 such that R02 = (1   f2)R01; where f2 is the growth disadvantage of the second
founder strain. We allow the two founder strains to evolve as described previously
(Monte Carlo based simulation) and at each generation n, we draw a sample of Ns
sequences with a probability of picking a descendant of founder strain i given by 
R0i
n 
R01
n
+
 
R02
n ; i = 1:2: (2.2.3)
and construct the intersequence Hamming distance distribution. In the single sce-
nario we consider here, we assume that infection starts with two founder strains with
dierent reproductive rates R01 = 4 and R02 = 2: At the time of infection, the Ham-
ming distance between the two sequences is xed at 50. At certain time points, within
a period of 20 generation, we sample Ns = 30 sequences and plot the histograms of
the observed intersequence Hamming distance frequencies, see gure 2.5 and gure
2.6.
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Figure 2.5: Observed intersequence hamming distance frequencies. At the specied
generation we randomly draw 30 sequences (from a uniform distribution) and compute
the intersequence hamming distance, continued in gure 2.6.
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Figure 2.6: Continuation of gure 2.5 of the observed intersequence hamming distance
frequencies.
Sampling at generation 18 (gure 2.6 shows the distribution of the intersequence
Hamming distance), we get sequences with the maximum Hamming distance of 6
which is consistent with that of an infection started by a single founder strain (see
gure 2.4 where the maximum Hamming distance at generation 18 is around 6). This
is expected because at generation 18, the probability of selecting the tter strain
(strain with an R0 of 4) is almost 1 and that of selecting a less tter strain is nearly 0.
In our simple model, we have only incorporated dierential tness and the model is
silent about the origin of this tness dierence. Eects of selection pressure due to the
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immune system can greatly inuence the population frequencies such that random
samples of genomes from populations seeded with multiple genotypes may resemble
those of single-genome infections. Due to innate dierential tness and selection by
immune system pressure, wrong deductions about the number of transmission events
may be made. In this simple example, analysis of the extent of viral diversity, some
time after infection by multiple founder strains, will resemble those of individuals
infected by a single strain because the ttest strain will be the dominant species.
Probability Generating Function Approach
In this framework, instead of considering the entire genome (all NB bases), we choose
a particular segment of the genome. For illustration purposes, we consider a single-
point mutation that occurs in a particular position in the viral genome, i.e. we
consider an articial viral genome with a single site, changes at the other remaining
sites are deemed irrelevant. In this scenario, we only have two types of infected cells
of relevance, the initially infecting strain (wild type) and a population of cells infected
with a virus carrying a sequence with a base change at the site of interest, i.e. the
single point mutant. We extend the size of the genome segment to three bases in
chapter 3. Branching processes have a recursive structure that makes it amenable
to analysis by generating functions [59]. Denitions and properties of generating
functions are given in Appendix A.
The population of the virus is modelled as a two-type process where the types
are 0 (wild-type infected cells) and 1 (mutant infected cells). The set of types is
T = f0; 1g: Independently of each other, each wild-type infected cell gives birth at
a rate  to a mutant infected cell and at rate (1   ) to a wild-type infected cell.
Similarly, a mutant infected cell gives birth at a rate  to a wild-type infected cell
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and at a rate (1   ) to a mutant infected cell. In our notation, superscripts will
denote the generation number and subscripts the type of the cell (0 for wild-type and
1 for the mutant). The transition matrix is given by
0@
P0 P1
P0 1   
P1  1  
1A; (2.2.4)
where the number of wild-type and single point mutant infected cells are given by P0
and P1; respectively. The ospring distribution for the wild-type and mutant infected
cells are: p0(k0; k1)  Bin(R0; 1   ) and p1(k0; k1)  Bin(R0; ); respectively. Here
p0(k0; k1) is the probability that the wild-type cell will give birth to k0 wild-type
cells with probability 1   and k1 mutant cells with probability ; assuming that at
death each cell gives birth to R0 cells (i.e. a binomial distribution). Using, equation
A.0.7 (Appendix A), we can derive the wild-type infected cell ospring probability
generating function (pgf) as:
g0(s0; s1) =
1X
k0=0
1X
k1=0
p0(k0; k1)s
k0
0 s
k1
1 ;
=
1X
k0=0
1X
k1=0

R0
k0

(1  )k0k1sk00 sk11 ;
=
1X
k0=0

R0
k0

(1  )s0
k0
s1
(R0 k0)
; (where k1 = R0   k0);
=

(1  )s0 + s1
R0
; (2.2.5)
where at the last step we have used the binomial theorem. Similarly, the probability
generating function for mutant infected cells can be shown to be
g1(s0; s1) =

s1 + (1  )s1
R0
: (2.2.6)
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Assuming that the population is started from a single wild-type infected cell, i.e. the
total population initial conditions fP0(0); P1(0)g = f1; 0g; we have
Gn0 (s0; s1) = g0

Gn 10 (s0; s1); G
n 1
1 (s0; s1)

;
=

(1  )Gn 10 (s0; s1) + Gn 11 (s0; s1)
R0
(2.2.7)
and
Gn1 (s0; s1) = g1

Gn 10 (s0; s1); G
n 1
1 (s0; s1)

;
=

Gn 10 (s0; s1) + (1  )Gn 11 (s0; s1)
R0
; (2.2.8)
assuming that each infected cell gives rise to exactly R0 new cells of generally all
types at generation n; with initial conditions G0i (s0; s1) = si for i = 0; 1: Here
Gn0 (s0; s1) = E

s
P0(n)
0 s
P1(n)
1
P0(0) = 1; P1(0) = 0
is the probability generating function of the population started by a single wild-type
infected cell and
Gn1 (s0; s1) = E

s
P0(n)
0 s
P1(n)
1
P0(0) = 0; P1(0) = 1
is the probability generating function of the population started by a single mutant
infected cell, where n  0; s0; s1 2 [0; 1]; P0(n) is the number of wild-type infected
cells and P1(n) the number of mutant infected cells at generation n: We can calculate
the following indicators of viral diversity in this framework:
1. Probability that a single mutant has never occurred. To calculate this prob-
ability, we use the following trick: Compute Gn0 (1; 0) in the model with type
transition matrix given in equation 3.2.1 but with state 1 (mutant) made an
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absorbing state, i.e.
0@
P0 P1
P0 1   
P1 0 1
1A; (2.2.9)
where the last row of the matrix is reset to (0 1). The modied process will go
to state 1 for the rst time exactly as the process would, but will stay there.
Denoting S0(n) = G
n
0 (1; 0) and also S1(n) = G
n
1 (1; 0); we have the following
recursive equations
S0(n) =

(1  )S0(n  1)
R0
;
S1(n) =

S1(n  1)
R0
; (2.2.10)
with initial conditions S0(0) = 1 and S1(0) = 0: This implies that S1(n)  0;
such that the probability of the event in question (mutant has never occurred)
is given by
S0(n) =

1  
Pn
i=1R
i
0
;
=

1  
 R0
R0 1

Rn0   1

: (2.2.11)
2. A related question of the mean time to the occurrence of a particular single
point mutant is given by
E(WT ) =
1X
n=0
S0(n);
=
1X
n=0

1  
 R0
R0 1

Rn0   1

: (2.2.12)
The median time to the appearance of a particular single point mutant is given
by solving the equation S0(n) = 0:5 for n: Thus the median time is
nm =
1
ln R0
ln

1  (R0   1) ln 2
R0 ln (1  )

: (2.2.13)
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3. The probability that a mutant infected cell is not currently present in the popu-
lation. This metric is precisely given by P0(n) = Gn0 (1; 0) which can be obtained
from the equations
P0(n) =

(1  )P0(n  1) + P1(n  1)
R0
;
P1(n) =

P0(n  1) + (1  )P1(n  1)
R0
; (2.2.14)
with initial conditions P0(0) = 1 and P1(0) = 0: This system of equations can
be easily solved numerically.
4. The expected number of infected cells present at generation n: For illustration
purposes, we consider the simplest case when R0 = 2: Denoting the matrix of
expected cell counts M(n) =

Mij(n)

;
Mij(n) = E

Pj(n)
Pk(0) = ik; k = 0; 1;
=
@
@sj
Gni (s0; s1)

s0=s1=1
; (2.2.15)
the expected number of type j ospring of a single type i cell in generation n
and ik is the Kronecker delta. The expected total number of cells present at a
particular time n is
PT (n) = E

P0(n) + P1(n)
P0(0) = 1; P1(0) = 0;
=
 @
@s0
+
@
@s1

Gn0 (s0; s1)

s0=s1=1
(2.2.16)
The expected number of mutant infected cells at a particular time is
m(n) = E

P1(n)
P0(0) = 1; P1(0) = 0;
=
@
@s1
Gn0 (s0; s1)

s0=s1=1
(2.2.17)
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Dierentiating the pgfs of the process, we obtain
M(n) = 2
0BB@ (1  )
@Gn 10 (1;1)
@s0

@Gn 11 (1;1)
@s1

@Gn 10 (1;1)
@s0
(1  )@Gn 11 (1;1)
@s1
1CCA ;
= 2
0BB@ 1   
 1  
1CCA
0BB@
@Gn 10 (1;1)
@s0
0
0
@Gn 11 (1;1)
@s1
1CCA ;
= M(n  1); n = 1; 2;    ;
= n; (2.2.18)
where  is the expected ospring matrix
 = 2
0B@ 1   
 1  
1CA ; (2.2.19)
and M(0) = I is the identity matrix derived from the initial conditions:
E

P0(0)
Pi(0) = 0i = 1; EP1(0)Pi(0) = 1i = 1;
E

P0(0)
Pi(0) = 1i = 0; EP1(0)Pi(0) = 0i = 0:
Matrix  is diagonalizable if there is a matrix, say V; such that V  1V = D is
a diagonal matrix. Then, as the matrix product is associative
n = V DnV  1: (2.2.20)
The two eigenvalues of the matrix  are 2 and 2(1  2) and the matrix of the
corresponding eigenvectors is given by
V =
0B@ 1  1
1 1
1CA (2.2.21)
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and its inverse given by
V  1 =
1
2
0B@ 1 1
 1 1
1CA ; (2.2.22)
such that
n =
0B@ 1  1
1 1
1CA
0B@ 2n 0
0 (2(1  2))n
1CA
0B@ 12 12
 1
2
1
2
1CA
=
0B@ 2n 1 + 2n 1(1  2)n 2n 1   2n 1(1  2)n
2n 1   2n 1(1  2)n 2n 1 + 2n 1(1  2)n
1CA : (2.2.23)
The expected total number of infected cells is given by
PT (n) = 2
n;
the expected number of mutant cells at generation n is
m(n) =
2n
2

1  (1  2)n

;
and the expected number of wild-type infected cells at generation n is
w(n) = 2n 1 + 2n 1(1  2)n;
for n = 0; 1; 2;    : Numerical simulations are carried out to compare to the
derived formulas and results are shown in gure 2.7. The two solutions (proba-
bility generating function framework and stochastic simulations) are in perfect
agreement.
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Figure 2.7: The probability that the mutant has never occurred (A) and (B) the
probability that the mutant is not currently present in the population. (C) Average
cell counts (wild-type (w) and mutant (m)) of 1000 runs of the branching process,
started by a single wild-type infected cell (with 95% condence intervals) and (D) the
expected cell counts given by the formulas for R0 = 2; mutation rate  = 10
 4: The
simulations and the formulas give the same result.
In general, if each infected cell produces R0 cells at the time of death, the mean
ospring matrix is
 = R0
0B@ 1   
 1  
1CA ; (2.2.24)
such that the two eigenvalues are given by R0 and R0(1   2): Similarly, the
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expected number of infected cells at every generation is given by the matrix
n =
0BB@
1
2
Rn0 +
1
2
(R0(1  2))n 12Rn0   12(R0(1  2))n
1
2
Rn0   12(R0(1  2))n 12Rn0 + 12(R0(1  2))n
1CCA : (2.2.25)
The expected total number of infected cells is given by
PT (n) = R
n
0 ; (2.2.26)
the expected number of mutant cells at generation n is
m(n) =
Rn0
2

1  (1  2)n

; (2.2.27)
and the expected number of wild-type infected cells at generation n is
w(n) =
Rn0
2

1 + (1  2)n

; (2.2.28)
for n = 0; 1; 2;    :
2.3 Viral Diversity Measures
In order to assess aspects such as the number of transmission events and resistance
evolution in HIV infections, various diversity indicators can be clinically measured.
Dierent questions require dierent diversity measures. Diversity measures are im-
portant and they can act as signals of epidemiological and clinical conditions. Among
these various indicators some may be very informative especially if a clinical condition
variation is a function of a metric indicator, e.g. appearance of particular mutations
(metric) can result in drug failure (clinical condition). We compare the dierent
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metrics that can be computed using dierent tools and suggest those that might be
of clinical or epidemiological signicance, i.e. those metrics that can be related to
prognosis.
From the two methodologies used to compute diversity outlined in the previous
sections, i.e. tracking individuals in the population (sequence evolution) and the use
of probability generating functions, a variety of diversity measures can be calculated.
Computing viral diversity indicators for each individual cell, diversity metrics such as
hamming distance distributions, average diversity, average divergence and sequence
identity do not depend on the virus reproductive rate, but depend on time only.
Asking questions about particular mutants in the probability generating function
framework, we can calculate diversity metrics such as the probability that a particular
mutant has never occurred or the probability of its non-existence in the population.
These diversity indicators which are readily calculated in the probability generating
function framework depend on both time and viral replication rate. Figure 2.8 shows
how dierent metrics depend on time and the number of new infected cells.
Instead of asking questions about probabilities of particular events or Hamming
distance distributions, alternatively we can ask questions about the mean and median
times to the occurrence of particular mutants in both paradigms. We have already
demonstrated how the mean and median waiting times are calculated in the proba-
bility generating function framework and now we use the full viral genome evolution
model (i.e. Monte Carlo Simulations only) to calculate the mean and median times to
the appearance of a particular single point mutation and compare these to the closed
form solutions obtained in the probability generating function framework.
Our numerical scheme is as follows: we assume that the mutation probability per
38
0 5 10 15 20
0
0.2
0.4
0.6
0.8
1
generations
S 0
0 5 10 15 20
0
0.2
0.4
0.6
0.8
1
generations
P 0
0 5 10 15 20
0
0.1
0.2
0.3
0.4
generations
div
er
ge
nc
e (
%)
0 5 10 15 20
0
0.1
0.2
0.3
0.4
generations
div
er
sit
y (
%)
A B
C D
Figure 2.8: The dependence of diversity metrics on time and virus replication rate.
The probability that a particular single point mutant A: has never occurred and B:
is currently absent for varying virus replication rates., i.e. R0 decreases from left to
right (R0 = 10 - dashed line, R0 = 6 - dashed and dotted line, R0 = 4 - dotted line
and R0 = 2 - continuous line). C: Average divergence, n: D: Average diversity, 2n;
where n is the generation number.
base is  = 10 4 and sequences are of length NB = 175: We generate the founder
sequence with weights [A C G T] given by [0.373 0.193 0.241 0.192], respectively.
Our substitution model is the Jukes and Cantor model [69]. We also assume that the
relevant single point mutation occurs when a base at a specic position X changes
to a particular base, for example, say C is the current base at X and the relevant
mutation occurs when base C changes to base G at position X. This can be achieved
straight away or through intermediate bases, A or/and T. The substitution rate is
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modied such that the probability that sequence i with base C at position X changes
to sequence j with base G at position X is given by P(i! j) = 1
3
 (the new mutation
rate in the closed form equation). We also assume that any changes at other remaining
sites other than that at site X in the sequence are regarded as not important, and
hence there is no dierential tness among infected cells carrying these sequences.
We start the simulation with one wild-type cell and when total population exceeds
106, we allow 106 cells (selected at random from a uniform distribution) to multiply
and sample another 106 from 106R0 new cells to contribute to the next generation.
For each value of R0; we run the model 1000 times and calculate the mean and median
times. The dependence of the mean and median times to appearance of a particular
single point mutant on replication rate is shown in Table 2.2 and gure 2.9. The table
and gure made counting only those simulations where the mutant appeared in the
population.
Table 2.2: Mean and median generations to the appearance of a particular single point
mutant calculated from the closed form probability generating function equations (cf)
(i.e. equations 2.2.12 and 2.2.13, respectively) and Monte Carlo simulations of the
synchronous model (sim). SE is the standard error that will give 95% condence
intervals.
R0 2 3 4 5 6 7 8 9 10
median (cf) 13.34 8.68 6.96 6.04 5.45 5.03 4.72 4.47 4.27
median (sim) 14 9 7 7 6 6 5 5 5
mean (cf) 13.54 8.99 7.31 6.41 5.83 5.43 5.12 4.86 4.67
mean (sim) 13.43 9.04 7.31 6.42 5.84 5.44 5.16 4.89 4.66
SE 0.11 0.07 0.06 0.05 0.05 0.04 0.04 0.04 0.04
Using the sequence evolution modelling framework to calculate calculate dierent
indicators of diversity, we observe that dierent metrics behave dierently. In this case
mean and median times to the appearance of particular mutations depend on both the
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Figure 2.9: Mean and median generations to the occurrence of a single point mutation
as given by the closed form solutions of the probability generating functions (i.e.
equations 2.2.12 and 2.2.13, respectively) and Monte Carlo simulations of the full
viral genome model, including 95% condence intervals.
number of generations and the number of infected cells at each generation (whereas
Hamming distance distributions depend only on the number of transcriptional events).
For these measures (mean and median times to the occurrence of particular genomes),
the probability generating function technique and the Monte carlo simulations of the
full viral genome framework coincide. We conclude that choosing measures of diversity
to compute is very important as dierent metrics behave dierently. Perhaps the
presence or absence of a particular variant (especially therapy defeating variants)
is prognostic. It is important to choose measures that correlate to the probable
outcome. Experiments can be performed to test whether there are correlations of
clinical outcomes and diversity measures.
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2.4 Conclusion
We have demonstrated that deterministic models are appropriate to investigate evo-
lution of common mutants. In environments where rare higher order mutations may
appear, deterministic models cannot explain appropriately the evolution of these rare
mutations. We develop a deterministic model with a few assumptions that allow for
a pseudo-stochastic component in chapter 4. The Poissonian waiting time is used to
rene the estimate for the impact of both transient and chronic treatment on strain
selection. The model is then extended to allow for non-exponential death rates and
for the transient survival of new genomes.
For discrete time models, we considered a simple synchronous model of viral evo-
lution and used two fundamentally similar frameworks to compute viral diversity
measures. The sequence evolution framework developed by Lee et al. [79] was suc-
cessful in assessing the degree of viral diversity during the early phase of infection.
However, the eect of assumptions such as dierential tness and selection pressure
can signicantly aect the overall conclusions. The probability generating function
paradigm oers the ability to eciently compute important indicators of viral diver-
sity without simulating the full range of individual level scenarios. Because of the
computational eciency and the fact that important measures of viral diversity that
can be computed from this paradigm depend on both time and virus replication rate,
we use this methodology in chapter 3 to model early events of HIV infection and
assess the impact of therapeutic interventions on the course of infection.
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2.5 Summary of Implications for the Biomedical
Field
Components of virus-host interactions are suciently complex that intuition alone is
insucient to understand the dynamics of such interactions [9]. Mechanistic models
attempt to explain real events, observed or not. Selection of modelling techniques
should be inuenced by the essence of the problem to be investigated to avoid misap-
plication such as using deterministic models to capture the dynamics of rare mutants
that exist as small sub-populations. Models need not be necessarily complex. Sen-
sible model building that incorporates realistic size and timescales, where possible,
avoiding having to estimate numerous microscopic properties such as molecular avidi-
ties can be very useful. Models with realistic assumptions can be experimental and
analytical tools. For example models have helped elucidate high viral turnover in HIV
infected individuals [120] and through coupling a mathematical model of HIV diver-
sication and single genome amplication (SGA) sequencing techniques, transmitted
HIV envelope sequences have been identied [71] . This work also showed that there
is a high barrier to infection, with approximately 80% of heterosexual infections ap-
parently started by a single virus, and that within 8 days of infection escape mutants
for envelope-directed CTLs appeared in the viral population. Also, models developed
in this work suggest that new measures of viral diversity, which correlate to prognosis,
should be sought, and monitored in clinical trials for vaccines for example.
Chapter 3
Modelling the Impact of Acute
Infection Dynamics on the
Accumulation of HIV-1 Mutations
3.1 Introduction
The extent of virus replication and immunopathological events during primary infec-
tion may be important determinants of the subsequent course of HIV disease [58].
Despite advances in elucidating the structure of HIV, its genetics and its mechanisms
of replication and survival in host immune system cells, the course of primary infec-
tion (the dynamics, timing and specicity of the immune response and the creation
and establishment of cellular reservoirs of virus) is only partially understood. In sex-
ual transmission, early events in HIV infection at the mucosal surface are critical to
the initiation and propagation of the disease [56].
Recent advances, through coupling data analysis and mathematical modelling,
have allowed the identication and characterization of the nature of the transmit-
ted virus. Results indicate that HIV-1 quasispecies that arise following a mucosal
infection are apparently consistent with a single transmitted strain [1, 71, 79]. The
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evidence of a high barrier to infection has created the enthusiasm and re-energized
the interest in targeting the early infection period with preventative or therapeutic
interventions such as vaccines [124] or pre-exposure prophylaxis (PrEP) [70]. Thera-
peutic vaccines can prime the immune system to develop antibodies and cytotoxic T
lymphocytes (CTLs) against the virus such that they are readily available to block
or control infection by attenuating virus replication. PrEP can block the early am-
plication process (when infected resting cells pass the virus to activated cells which
are critical for the infection process to start) after the virus has permeated through
the mucosa [56] or restrict viral expansion by reducing the reproductive rate of the
virus, preventing chronic infection.
The main clinical benet of intervention at the early phase of HIV-1 infection is
to block infection or contain early viral spread in the case of a breakthrough infec-
tion. There are undesirable consequences of undeterred viral replication during early
infection, for example, 1) massive depletion of the CD4+ T-cell population, in partic-
ular within the gut-associated lymphoid tissue (GALT) [14, 96, 100] and 2) probable
early establishment of viral reservoirs [37]. The establishment of viral reservoirs is a
likely barrier to eradication of the virus [20]. Also, undeterred viral replication during
early HIV infection seems associated with amplied transmission probability per sex
act, and the timing of this peak in infectiousness means that patients are unlikely
to know their HIV status at the time of this peak. Massive depletion of the CD4+
T-cell population is harmful for the patient: e.g. the risk of tuberculosis (TB) disease
seems to be much higher in acutely infected people than in HIV negative people [26].
Existing analysis and modelling of early infection is largely driven by the kind of
questions being addressed. For example, models of random mutations have been used
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successfully to assess viral diversity as an indicator of the number of infection events
or founder strains [71, 79]. According to these models, in homogenous infections, i.e.
infections initiated by a single founder strain, the hamming distance (the number of
bases at which any two sequences dier) distributions are essentially Poisson distri-
butions. Models of sequence evolution have also been used to assess viral diversity
during the chronic phase [80, 132]. Using recent acute HIV-1 infection data and a
codon model of sequence evolution, a group of researchers found evidence of positive
selection which appeared to be driven by cytotoxic T lymphocyte responses [154].
Also, population dynamic type models, mainly ordinary dierential equations,
have been used to study viral dynamics of early HIV-1 and SIV infections. Some
of these models have been used to estimate viral growth rates, basic reproductive
numbers and post peak decay rates [87, 114, 128]. Such models have also been used
to understand the role of early immune responses in HIV infection [6, 47, 141]. These
models have helped to dene the challenge that immune responses and therapeutic
interventions have to overcome to defeat HIV early in infection. However, these
models make specic assumptions about many intra-cellular processes, such as cell
entry rates and lifetime distributions, that are not directly observable.
As an alternative to the use of diversity, divergence, sequence identity and maxi-
mum hamming distance as correlates of the number of transmission events, we propose
a new metric of diversity which may relate to prognosis. Whilst every possible single
point mutation in the viral genome may occur in each generation, we are interested in
computing the probability of appearance of particular mutations in the viral genome,
i.e. we can ask about the probability that a particular mutant has never occurred or
is currently present. Viral genetic changes can result in increased virulence, increased
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cell tropism, escape from host immune/drug pressure [32, 84, 140] and may conse-
quently lead to treatment failure [67]. One study has reported that low pre-treatment
diversity (diversity dened by pairwise comparisons of nucleotide substitutions per
site) is also associated with control of viremia during subsequent treatment interrup-
tion and low viral replication capacity [68]. Accumulation of quasispecies can also
result in alterations in receptor usage, in particular CCR5 and CXR4, and this switch
in receptor usage is correlated with a faster progression of the disease [84, 132]. Also
these new mutations are likely to be archived in latently infected cells and are unlikely
to be eliminated by HIV-1 immune responses and antiretroviral therapy, even after
treatment intensication [31].
Previously, some authors calculated the expected frequency of resistant virus and
showed that the likelihood of generating resistant mutants during treatment is less
than the likelihood that such mutants are present before treatment is initiated [13,
112, 127]. A simple calculation of waiting times to the appearance of mutants before
and during treatment shows that it is highly unlikely that new mutants appear during
suppressive therapy (see chapter 4). Unabated viral replication results in a continuous
accumulation of variants which may persist at very low frequencies. The pre-existing
minority mutations which may not be detected by standard bulk sequencing genotypic
assays in both drug-naive and drug-experienced persons, e.g. thymidine analogue
mutations (TAMS), have shown to be signicantly associated with virologic failure
[67, 101].
A birth and death process model of viral growth [125] was used to assess the prob-
ability of appearance of resistant mutants. In their framework, the authors calculated
the total number of replications until a specic mutant rst appeared. From direct
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simulations in [125], results show that common mutants (one point and two point
mutants) were likely to appear early during acute infection and three point mutants
may emerge around the peak of viremia but disappeared at the set point. However,
calculating the number of replication cycles may not be a good metric if immune
eects are considered because immune control impact can change the absolute time
until appearance of a specic mutant but not the number of replication cycles. In this
model [125], the number of infected cells changes by one at a time. This assumption
is unlikely suited for virus proliferation as noted in [57].
In this chapter, we use a multi-type Galton-Watson branching process (GWBP)
in a varying deterministic environment. In our branching process model, the number
of ospring is time dependent (in discrete non-overlapping generations). Multi-type
branching processes have been used to calculate the risk of escape that comes from
pre-existence of resistant mutations held in a mutation-selection equilibrium for a
population of organisms challenged by a biomedical intervention [64, 65], mutation
accumulation in mitochondrial DNA and the polymerase chain reaction [75, 117]. The
Galton-Watson process has a simple recursive structure that makes it amenable to
analysis by generating functions, hence we can derive ensemble level probabilities of
diversity without the need for calculating many population level `realizations'.
Our model dierentiates from previous studies [64, 65, 125] in that it parame-
terizes the dynamics through an eective reproductive number of ospring per indi-
vidual. This makes it relatively straightforward to model changes between scenarios
corresponding to interventions, whose impact on the course of infection can then be
heuristically described. By contrast, previous authors have tended to dene specic
microscopic dynamics, such as exponential growth, or mass action, with particular
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rate constants that have not been reliably measured. We can tune our eective re-
productive number over a period of several weeks/months post infection to obtain
realistic initial viremic peaks and set points, without having to unpack the underly-
ing combination of target cell depletion and immune system responses, as it is only
the infected cell population which we need to model in order to quantify opportunities
for evolution.
The main focus here is calculating probabilities of appearance and the likelihood
of existence of genomes which potentially arise from infections initiated by a single
strain. We explore how the dynamics of early infection aects the accumulation of
mutations which lay the seeds for long term evolution of drug resistance and immune
system evasion. These models may be useful to test the biological eectiveness of
early interventions (PrEP or vaccines) in the case of a breakthrough infection. There
is concern that PrEP or imperfect vaccines may lead to clinically disadvantageous
selective pressures during HIV transmission. The details of how a topical exposure
becomes a systemic infection are beyond the scope of this analysis. In the case of a
drug or vaccine naive infectious partner, it may be that the relevant mutations are
absent, or present only in trace quantities, so that to rst order there is little selective
pressure aecting what, for the purposes of the present analysis, is the founding strain
or wild-type, dened by a narrow view of a small portion of the viral genome.
3.2 A Model of Viral Diversity
In our model, we consider an infection that is started by a single infected cell carrying
a particular sequence with a certain number of bases. We focus on a small segment of
the viral genome where changes or mutations at these particular sites are relevant and
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lead to key variants. Any changes at the other remaining sites are deemed irrelevant
in our model. The mutation rate per nucleotide is given by a parameter : The
branching process model is as follows: one infected cell initiates the process. On
replication, each cell produces new cells; the type of each new daughter cell may or
may not be the same as that of the parent cell, i.e. infected cell populations evolve
as a pure stochastic process with random choices for the type of ospring.
3.2.1 Single Mutation
We start by considering a single-point mutation that occurs in a particular position
in the viral genome, i.e. our articial viral genome has a single site. In this scenario,
we only have two types of infected cells of relevance, i.e. the initially infecting strain
(wild type) and a population of cells infected with a virus carrying a sequence with a
base change at the site of interest (single point mutant). The mutation matrix with
transition probabilities is given by:
0@
P0 P1
P0 1   
P1  1  
1A; (3.2.1)
where the number of wild-type and single point mutant infected cells are given by P0
and P1; respectively. This process is a two-type Galton-Watson process (see Appendix
for details). We assume that the two types have dierent replication rates and the
mean number of ospring for each type may change from generation to generation, i.e.
the two eective reproductive numbers are R0(n) and R1(n) for the wild-type strain
and mutant, respectively. The eective reproductive number is the average number
of new infections caused by one infected cell at a given time/context in a population
that is not necessarily wholly susceptible. In our notation for probability generating
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functions (pgfs), superscripts will denote the generation number and subscripts the
type of the cell (0 for wild-type and 1 for the mutant).
The ospring distributions for the wild-type and mutant infected cells at every gen-
eration are binomial, i.e. p0(k0; k1)  Bin(R0(n); 1 ) and p1(k0; k1)  Bin(R1(n); );
respectively, where pi(k0; k1) is the probability that a cell of type i = 0; 1 has k0 o-
spring of type 0 and k1 of type 1. Using equation A.0.7, the pgf for the wild-type
infected cell ospring at generation n is given by
gn0 (s0; s1) =
1X
k0=0
1X
k1=0
p0(k0; k1)s
k0
0 s
k1
1 ;
=
1X
k0=0
1X
k1=0

R0(n)
k0

(1  )k0k1sk00 sk11 ;
=
1X
k0=0

R0(n)
k0

(1  )s0
k0
s1
R0(n) k0
;
=

(1  )s0 + s1
R0(n)
; (3.2.2)
where k1 = R0(n)   k0 and at the last step we have used the binomial theorem.
Similarly, the pgf for the mutant infected cell ospring is given by
gn1 (s0; s1) =

s0 + (1  )s1
R1(n)
: (3.2.3)
Assuming that the population is started from a single wild-type infected cell, we
have the process initial conditions given by fP0(0) = 1; P1(0) = 0g: We can use the
iteration
Gni (s) = G
n 1
i

gn0 (s); g
n
1 (s)

; n = 2; 3;    (3.2.4)
for i = 0; 1; where s = (s0; s1); to derive the pgf specifying the distribution law of the
number of cells at every generation. The marginal laws for subsets Pi can be obtained
by setting respective arguments of the pgf equal to 1 [75]. The derived marginal pgf
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constructs can then be used to calculate probabilities of interest. The marginal pgf of
mutant infected cells in a process initiated by a single wild-type infected cell is given
by Gn0 (1; s1); such that the probability that a mutant infected cell is not currently
present at generation n in the population is precisely given by P0(n) = Gn0 (1; 0): To
calculate the probability that a single point mutant has never occurred, we use the
following trick: we compute Gn0 (1; 0) in the model with type transition matrix given
in equation 3.2.1 but with state 1 (mutant) made an absorbing state, i.e. where the
last row of the matrix is reset to (0 1). The modied process will go to state 1 for the
rst time exactly as the process would, but will stay there. Letting S0(n) = G
n
0 (1; 0)
with the initial condition S0(0) = 1; we have the sequence
S0(1) =

(1  )
R0(1)
;
S0(2) =

(1  )(1  )R0(2)
R0(1)
;
S0(3) =

(1  )

(1  )(1  )R0(3)
R0(2)R0(1)
; (3.2.5)
S0(4) =

(1  )

(1  )

(1  )(1  )R0(4)
R0(3)R0(2)R0(1)
;
... =
...
and so on, such that the probability that the mutant has never occurred is given by
S0(n) =

1  
Pn
i=1
Qi
j=1R0(j)
; (3.2.6)
which has boundary conditions S0(0) = 1 and S0(1) = 0: The exponent is the
total wild-type infected cell population size after n generations. Equation 3.2.6 is the
\survival" function (\survival" means no mutant present). Let a non-negative random
variable T represent the number of generations until there is a mutation, then the
cumulative distribution function, which gives the probability that the mutation has
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occurred by generation n; is given by Pr(T  n) = 1   S0(n): Thus the density is
given by f(n) = S0(n 1) S0(n): The expected time (generation) to the appearance
of a single point mutant is given by:
E(WT ) =
1X
n=0
nf(n);
=
1X
n=1

1  
Pn
i=1
Qi
j=1R0(j)
: (3.2.7)
3.2.2 Multiple Mutations
For higher order mutations, we choose a small portion of the viral genome with three
sites where we assume a founder strain (wild-type), the possibility of three single-
point and three double-point mutants, and also the possibility of multiple mutations
which lead to a three point mutant that is reachable by dierent pathways (see Ap-
pendix C for the three point mutation network matrix). This is just one example
of a phylogenetic tree; any tree can be easily accommodated in our framework by
modifying the mutation matrix. We are using the minimum number of mutations
within which we can describe the interplay between common mutations, unviable in-
termediate mutations, and `compensatory' mutations. It will be interesting to apply
this approach to high quality clinical data, demonstrating how mutations accumulate
to provide increasing resistance [67, 101, 129, 136].
From system C.0.5 in Appendix C, the result that is relevant to our setting is the
joint pgf of the numbers of cells of all types, present at generation n in the process
initiated by a single wild-type infected cell given by Gn0 (s); where s = (s0;    ; s7): In
our notation, f0g represents wild-type infected cells, f1,2,3g three single point mutant
infected cells, f4,5,6g three double point mutant infected cells and f7g triple point
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mutant infected cells. We can derive recurrent equations for:
1. the marginal joint pgf of the numbers of all single point mutant infected cells
as Gn0 (s)jsj=1;j 6=f1;2;3g; such that the probability that no single point mutant
infected cells are present at generation n is given by
Psp0 (n) = Gn0 (s); (3.2.8)
using substitutions s = (1; 0; 0; 0; 1; 1; 1; 1):
2. the marginal joint pgf of the number of all double point mutant infected cells as
Gn0 (s)jsj=1;j 6=f4;5;6g; where the probability that no double point mutant infected
cells are present at generation n is given by
Pdp0 (n) = Gn0 (s); (3.2.9)
using substitutions s = (1; 1; 1; 1; 0; 0; 0; 1):
3. the marginal pgf of triple point mutant infected cells as Gn0 (s)jsj=1;j 6=7; where the
probability that no triple point mutant infected cells are present at generation
n is given by
P tp0 (n) = Gn0 (s); (3.2.10)
using substitutions s = (1; 1; 1; 1; 1; 1; 1; 0):
3.3 Early Infection Scenarios
The eective reproduction number is of great importance in facilitating quantitative
assessment, in real time, of the impact of intervention strategies on the course of dis-
ease progression [53]. In order to explore the impact of intervention early in infection
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(such as eects of vaccines or PrEP) on the probability of diversity, we choose var-
ious proles of the eective reproduction number and calculate the probability that
particular mutants are currently absent from the population. We assume that the
eective reproduction number is given by the following continuous piecewise linear
function:
R(n) =
8>>>>>>>><>>>>>>>>:
R0 if n < ng
(R0  Rm)(np   n)
np   ng if ng  n < np
Rm if np  n < ns
1 if n  ns
(3.3.1)
schematically shown in gure 3.1. Here R0 is the basic reproductive ratio, dened
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Figure 3.1: A generic prole of the eective reproductive number. Parameters: ng 1
is the initial number of generations when infected cells replicate undeterred, np   1
is the number of generations taken to reach the maximum number of infected cells
(peak) and ns is the number of generations it takes for the infected cell population
to settle at steady-state, with each productively infected cell producing on average a
single new infected cell. Varying ng and R0 we can mimic the eects of a vaccine and
PrEP strategies.
as the number of new infections caused by one infection in an extremely susceptible
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population, i.e. at the beginning of infection [4]. We have R(n)  R0; with the upper
bound and n is the generation number. This ospring production function gives three
stages in the infection process, i.e. exponential growth up to generation np   1 (time
to attain peak viral levels), decline from generation np up to generation ns 1 (time to
reach set point) with a minimum ospring production of Rm and nally the infection
incidence remains approximately constant at set-point starting from generation ns:
We obtain the following dynamics from this function: an exponential expansion
soon after infection until generation ng   1; (we call this the period of unrestrained
growth) which may be attributed to the unlimited availability of target cells and the
absence of immunological control. Subsequently, immune control becomes activated,
together with the gradual depletion of the target cell pool hence the decline in the
number of ospring produced. There is an attenuated viral expansion up to generation
np   1: During the period between np and ns generations, we have R(n) < 1; i.e. the
chain reaction is subcritical due to immune system control and/or loss of target cells.
We can vary the four parameters in this simple function to mimic aspects such as: the
time the immune system comes into eect, the period at which the immune system
can suppress viremia, the time to reach peak and set-point, and the height and width
of the viremia peak. Using the ospring eective reproductive function, the number
of infected cells at generation n is given by:
P (n) = bP (n  1)R(n)c ; for n  1; (3.3.2)
where bxc = maxfm 2 Zjm  xg is the oor function where Z is the set of integers.
This slight modication of the total number of infected cells in each generation allows
us to retain the integer counts of infected cells. Unless stated in the scenarios, we
assume that all types of infected cells have the same number of ospring at generation
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n - i.e. no dierential tness among variants.
Also, we can relax the assumption that there is no dierential tness among
variants and explore the impact of intermediate mutants tness bottleneck on the
probability of viral diversity. We let the growth disadvantage of mutant i relative to
the wild-type be given by fi = 1   R0i=R0; for i = 1; 2; 3 representing single point,
double point and triple point mutants, respectively. R0 is the basic reproduction rate
of the wild-type strain. Now the eective reproduction number for the mutants will
be given by R0i(n) and we assume that there is no dierential tness at steady state.
At steady state each infected cell produces one new cell. For illustration purposes, we
assume that the reproductive ratios of the wild-type and the triple point mutants are
equal, i.e. R03 = R0. Therefore, this investigates the eect of intermediate mutants'
tness bottleneck on the evolution of a higher order mutant.
To investigate the eects of biomedical interventions, we choose a base scenario
that may correspond to the standard course of disease progression and then explore
perturbations that inuence viral diversity. Our parameters are assigned values to
produce realistic population sizes and timescales observed clinically. The inspiration
is to produce dierent phases of viral growth after a breakthrough infection, i.e. a
viremic peak of a couple of weeks, viral load to decline and to stabilize at equilibrium
(stages of early HIV infection [36]). With these dierent parameter values, we can
explore important regimes of classes of models which are consistent with important
overall features of the system. This analysis captures regimes of impact, on diversity,
of PrEP and vaccine strategies.
Our base scenario is generated by the eective reproduction number prole given
by the following parameters: R0 = 6; ng = 8; np = 20 and ns = 28: In all the gures,
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we assume a per base mutation probability () of 3 10 5 [92]. The prole, explicit
stochastic simulations and recurrent equation solutions for probability of diversity
(equations 3.2.8, 3.2.9 and 3.2.10) are shown in gure 3.2. In this gure, we are com-
paring solutions derived from the use of pgfs, which capture likelihoods of existence
of particular genomes, against full explicit stochastic simulations. Figure 3.2(B) is a
single run of the full branching process. Simulations and recurrent equation solutions
are in good agreement, where single and double point mutations are overwhelmingly
likely to appear early and most of the times (about 80%), the triple point mutant
does not appear around the peak viral load (similar to results obtained by Ribeiro
and Bonhoeer [125]). This illustrates that using pgf equations rather than explicit
simulations, we can eciently obtain answers to key questions about viral evolution.
Therapeutic interventions may provide inhibition from the very onset of viral entry
(e.g. PrEP) or attenuate viral load during the course of infection (e.g. vaccine) and
may signicantly change the course of disease progression. We investigate the impact
of these intervention programmes by calculating viral diversity on either side of our
'threshold', i.e. base scenario. Our models capture well known semi-quantitative
aspects of HIV infection such as the magnitude and duration of early viremia which
itself parameterizes opportunities for mutation. Using several model scenarios that we
regard as clinically relevant, we demonstrate various regimes of 'response' of evolution
to 'intervention' in a framework in which a modest number of assumptions create
the scenarios.
58
0 10 20 30 40 50
0
2
4
6
generations
R
0 10 20 30 40 50
0
2
4
6
8
10
12
generations
log
10
 
inf
ec
te
d 
ce
lls
0 10 20 30 40 50
0
0.2
0.4
0.6
0.8
1
generations
Pr
(no
 m
uta
nt)
A B
C
wild−type
single points
double points
Figure 3.2: A comparison of pgf recurrent equation solutions and explicit stochastic
simulations. A : Viral reproduction rate prole when R0 = 6; ng = 8; np = 20; ns =
28: B: A single realization of the 8-type branching process generated by prole in panel
A, showing the dynamics of wild-type, three single point mutant and three double
point mutant infected cell populations. We assume a per base mutation probability
of  = 3 10 5: C: The probabilities of non-existence of i) single-point mutants (Psp0
- dashed curve), ii) double point mutants (Pdp0 - dotted curve) and iii) triple point
mutant (P tp0 - solid line). There is no dierential tness among variants, i.e. all viral
strains have the same eective reproduction number prole given in panel A. Panels
A and C make up panel B in both gures 3.3 and 3.4.
3.3.1 Vaccine Eects
We assume that a hypothetical vaccine intervention's impact can resemble trends
that have been observed in SIV vaccinated animal models, i.e. it causes the attenu-
ation of viral load that results in reduced peak and set-point. Clinical trial data on
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SIV animal models has shown that there is a signicant dierence between viral load
growths, peak viremia and early viral set point of vaccinated and unvaccinated ani-
mals [81, 151]. In general unvaccinated animals had fast growth, high peak viremia
and often high early viral set-point compared to the vaccinated animals. A vac-
cine can prime and/or boost immune function of an individual that can limit the
rate of viral replication. To mimic the eects of vaccine-induced immunity using our
framework, we vary the time of unrestrained viral growth (ng) and explore its im-
pact on diversity, see gure 3.3. Reducing ng in our base case to 1 (which resembles
an ever ready vaccine-induced immune control at infection), signicantly increases
the chances of extinction of even common (single point and double point) mutants
later during chronic infection. Delaying viral control, i.e. increasing ng in our model,
results in a higher likelihood of mutation accumulation and persistence.
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Figure 3.3: The eects of varying the time of unrestrained replication (ng) on the
probability of mutations being currently absent from the population. In each panel,
we show the attenuated viral replication prole and the corresponding viral diversity,
i.e. probability of non-existence of i) single-point mutants (Psp0 - dashed line), ii)
double point mutants (Pdp0 - dotted line) and iii) triple point mutant (P tp0 - solid
line). The other parameters are xed: R0 = 6; np = 20; ns = 28 and the per base
mutation rate is  = 3  10 5: A: eects of early intervention, B: baseline scenario
and C: eects of late intervention.
3.3.2 PrEP Eects
PrEP is one of the options currently being tested as part of the eorts to identify
additional tools to reduce the risk of HIV acquisition. The rationale of this approach
is to inhibit HIV replication from the moment of infection and this may help to avert
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chronic or persistent infection. Drugs such as tenofovir disoproxil fumarate which can
be used on its own or in combination with emtricitabine taken daily are candidates
for oral preventative drugs. PrEP trials in macaques [44] and humans [121] reported
evidence of ecacy. We vary the virus's basic reproduction ratio, R0; and assess its
impact on accumulation of mutations. Figure 3.4 shows PrEP scenarios varying in
eectiveness and the associated impact on viral diversity. Eects that reduce the
amplication process early (reducing virus's reproduction rate) signicantly reduce
viral tness and consequently reduce viral diversity. Unabated and rapid replication
(high virus reproduction rate) soon after infection quickly leads to high diversity.
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Figure 3.4: The eects of varying the basic reproductive number (R0) on the prob-
ability of mutations being currently absent from the population. In each panel, we
show the attenuated viral replication prole and the corresponding viral diversity, i.e.
probability of non-existence of i) single-point mutants (Psp0 -dashed line), ii) double
point mutants (Pdp0 -dotted line) and iii) triple point mutant (P tp0 -solid line). The
other parameters are xed: ng = 8; np = 20; ns = 28 and the per base mutation rate
is  = 3 10 5: A: eects of reduced reproductive number, B: baseline scenario and
C: eects of high reproductive number.
Incorporating dierential tness among variants in both vaccine and PrEP scenar-
ios, we explore the impact of intermediate mutants tness bottleneck on the proba-
bility of non-existence of the triple point mutant during the chronic state of infection.
For illustration purposes, we choose the worst case scenarios in both the vaccine and
PrEP strategies (i.e. gure 3.3(C) and gure 3.4(C)). As shown in the two contour
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plots (gure 3.5 and gure 3.6), high tness costs for early events are important in
reducing diversity later on. High tness cost for single point mutants signicantly
reduces viral diversity (measured as the probability that there is no triple-point mu-
tant at chronic stage, i.e. at generation 50) compared to high tness costs for double
point mutants.
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Figure 3.5: A contour plot for the probability of non-existence of a triple point mutant
at generation 50 as a function of intermediate mutants tness costs (for scenario 3.3
(C)). We assume that the reproductive ratios of the wild-type and triple point mu-
tants are equal, therefore this investigates the eect of intermediate mutants' tness
bottleneck on the evolution of a higher order mutant.
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Figure 3.6: A contour plot for the probability of non-existence of a triple point mutant
at generation 50 as a function of intermediate mutants tness costs (for scenario 3.4
(C)). We assume that the reproductive ratios of the wild-type and triple point mu-
tants are equal, therefore this investigates the eect of intermediate mutants' tness
bottleneck on the evolution of a higher order mutant.
3.4 Conclusion
Using a simple model, we have calculated viral diversity (dened as the probability of
existence of particular mutants) under various scenarios. It is useful to identify and
characterize particular mutations that can evolve during the early stages of infection.
We relate the exploration to the eects of interventions on mutation accumulation
and have shown that early intervention has a profound impact on the evolution of
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the virus. This is another dimension to investigate whether the unrestrained growth
of virus during early infection generates sucient diversity which may relate to prog-
nosis.
An ever ready intervention at the time of infection may not prevent the occurrence
of single point and double point mutations but has a very signicant impact on their
persistence, i.e. attenuating the founder virus results in reduced diversity. Delaying
viral control guarantees the persistence of common mutants but does not necessarily
mean higher order mutations (e.g. triple point mutants) will occur or will persist
if they appear. Further delay of viral control will result in a higher likelihood of
mutation accumulation and persistence. Our scenarios include 1) the eect of a
vaccine on the immune system (i.e. a vaccine that can prime the immune system to
develop antibodies or CTLs against the virus) being present at the very beginning
of infection or immune response that gradual develops and 2) therapy that inhibits
infection of target cells. We would also like to mention that there is also a danger of
drug resistance if individuals continue to take PrEP drug after they became infected
with HIV, they could develop resistance forms of the virus because of suboptimal
suppression.
Branching process models have also been used to estimate the probability of suc-
cess or failure of a biomedical intervention basing on assumptions that mutation rates
are small, mutations exist in mutation-selection equilibrium and all intermediate mu-
tants carry subcritical tness costs [64, 65]. These studies characterized the ecacy of
interventions in terms of a critical population size, typically relying either on substan-
tial simplifying assumptions which make it possible to derive closed form solutions
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[64, 65] or complex models which involve explicit simulation of the infection dynam-
ics [125]. In the present approach, there is no need to perform explicit simulations,
yet we can calculate what appear to be the crucial indicators of diversity, within a
model that captures known semi-quantitative aspects of HIV infection such as the
magnitude and duration of early viremia - which itself parameterizes opportunities
for mutation.
Our analysis is a new way to study replication/viral diversity where the number of
ospring per individual is given by an eective reproductive number function. This
allows us to model the impact of interventions on the course of infection, without
having to make specic assumptions about many microscopic details. Within this
framework, we explored scenarios demonstrating the interplay between common, in-
termediate and rare mutations, by calculating statistical indicators of diversity. This
method obtains impressive eciency by making use of recursion relations for en-
semble level probability generating functions without the need for calculating many
population level `realizations'.
An HIV vaccine is still years ahead, therefore treatment is one of the immediate
therapeutic remedies at our disposal. The brighter side is that current drug proles
are favorable (dosing convenience, e.g. multi-pills in one and improved safety proles)
and patients can now easily adhere to prescriptions but there is evidence that pre-
existence of mutations before therapy is a crucial part of the long term prognosis
[67, 86]. At the rate at which diversity increases, by the time patients start treatment
(at the late stage of infection, usually after 5 to 10 years if treatment is initiated during
symptomatic phase), a lot of mutations could have been generated and probably
archived too.
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Early treatment might help retard accumulation of resistance and therefore might
cut into the opportunity for viral replication to produce treatment defeating variants.
Also, studies have shown that early treatment reduces the size of the latent viral
reservoir [89, 137]. Initiation of treatment early is also associated with the preser-
vation of the immune function [63], a benet to the patient which can increase the
probability of cure as well as decreased transmission within the population. Reducing
the number of mutants in the viral population may help increase treatment ecacy
and options for patients. If treatment should be started to benet from low prevalence
of mutants, \universal treat and test" approach [50] might be a good idea although
\hit hard and early" tactic [62] would be the best.
This simple analysis supports both proponents of \hit hard and early" and \uni-
versal test and treat" in that early treatment-induced control of viremia will help
reduce viremia of homogenous population therefore reducing chances of further mu-
tation accumulation. Waiting for years to initiate treatment gives the virus enough
time to accumulate compensatory mutations which will reduce treatment ecacy
later on. This is in line with the clinical assumption that the window of opportunity
is from transmission to peak viremia and after that it becomes a point of no return
[99, 153].
Although such analysis may be probably too simplistic for the complex dynamics
of HIV, we have shown that including, even conservative assumptions such as equal
tness for all variants, there is still a chance that higher order mutants generated early
in infection might eventually go to extinction. There is an overwhelming likelihood
that variants generated early in infection and are present in low quantities will go to
extinction during viral decline due to either limited target cell population or immune
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control provided that it is cross reactive. The branching process construct incorpo-
rates a fair amount of the complexity of the stochastic reality. In our scenarios, we
chose an arbitrary tipping point between the good and the bad regimes, and our model
seems heuristically sensible. Our model captures realistic overall population sizes and
timescales characterizing the typical course of infection. It remains to be seen if our
framework can be quantitatively accurate if applied to detailed clinical/experimental
scenarios from careful studies.
There are some limitations to our approach. We have modelled populations with
discrete and non-overlapping generations, whereas in HIV dynamics, individual in-
fected cells die and reproduce at random times. Also, as noted previously by Iwasa et
al. 2003 [64], multi-type branching processes describe accumulation of mutations in
independent lineages, so that the model is unable to describe recombination, which
can be crucial in viral evolution. Nevertheless, this analysis captures regimes of im-
pact, on diversity, of some topical intervention strategies.
3.5 Summary of Implications for Public Health
According to the analysis in this chapter, there may be substantial clinical benets
for patients who are on PrEP but happen to be infected, as it appears that the initial
drug levels can substantially impede viral replication and hence long term prospects
for viral evolution. This could be investigated further by following up patients infected
during studies and monitoring their viral diversity over longer periods of time, such
as in the recent (IPreX) trial (Grant et al. [51]).
Chapter 4
Chronic and Transient
Antiretroviral Therapy Selecting
for Common HIV-1 Mutations
Substantially Accelerates the
Appearance of Rare Mutations
4.1 Introduction
The rapidity of human immunodeciency virus (HIV) replication, combined with its
high reverse transcriptase error rate [41], leads to rapid viral evolution, in particu-
lar the emergence of drug resistance. Treatment that is unable to suciently inhibit
viral replication allows the appearance and/or selection of drug-resistant strains. Fur-
ther accumulation of resistant variants may limit therapeutic ecacy and jeorpadize
subsequent treatment options.
A single dose nevirapine (NVP) regimen for prevention of mother to child trans-
mission (PMTCT) is a well known example of a suboptimal regimen that inevitably, if
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temporarily, exerts selective pressure in favour of resistant strains. This is still a ma-
jor concern in developing countries where a prophylactic regimen of single dose NVP
is widely used for PMTCT [74]. Given the high frequency of mutation, some minority
resistant mutants are always preexisting, albeit in trace quantities, at the moment
therapy is initiated. Because of the long half-life of single dose NVP, with blood levels
detectable up to 2-3 weeks after exposure [25, 107], the duration of sub-therapeutic
NVP concentrations may present a signicant hazard of developing resistance for
the mother. There is a risk of treatment failure after single dose NVP exposure, if
the treatment includes a non-nucleoside reverse transcriptase inhibitor (NNRTI) [39].
The question arises whether, and to what extent, a transient treatment-induced boost
to an otherwise marginal subpopulation results in increased risk of accumulation of
further resistance mutations that could potentially increase the risk of subsequent
NNRTI-based treatment failure.
In the search for better PMTCT regimens, improved ecacy has been demon-
strated for a number of short course regimens for PMTCT in resource-limited set-
tings. For example, 1) use of single dose NVP with additional short course of zidovu-
dine/lamivudine during 3-7 days postpartum [97], 2) addition of single dose NVP
to zidovudine short course during the antenatal period [88] and, recently, 3) use of
intrapartum single dose of combined tenofovir/emtricitabine taken after antenatal
short course of zidovudine plus intrapartum single dose NVP [18]. These regimens
improve on single dose NVP either in ecacy for PMTCT or reduction of NVP re-
sistance in the mother, or both. However they appear suboptimal in that they select
for NNRTI-resistant strains and therefore increase the mothers' risk of virologic fail-
ure for subsequent NNRTI-based therapy. For example, in the MASHI study[88] a
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total of 218 women started post partum NVP-based therapy after they had received
zidovudine from 34 weeks of gestation through delivery. Of these, 112 had received
single dose NVP, whilst the rest had received a placebo during labour. After 6 months
of post partum treatment with a NVP-based regimen, women without prior NVP ex-
posure were less likely to have virologic failure compared to women who had received
intrapartum NVP. Strikingly, of women who started NVP-based therapy within 6
months, 41.7% from the single dose NVP group, but none from the control group,
had virologic failure.
In-vivo mathematical models have been useful in exploring the evolution of drug
resistance, suggesting that signicant evolution can occur during treatment or before
initiation of treatment [3, 12, 13, 126, 130, 134, 155]. Based on the models, the authors
argued that chances of resistance evolving during treatment are small compared to
chances of resistance evolving before suppressive therapy. However these studies did
not explore, in any dynamically consistent framework, the emergence/accumulation
of multiple mutations in a possibly non constant environment. In this chapter, we
extend these standard models to explicitly investigate the consequences of population
dynamical eects amongst common resistant mutants. We show how the deterministic
dynamics of the common mutants aects the time taken to produce the rarer mutants.
We start from an ordinary dierential equation (ODE)-type model of in-vivo viral
replication in the deterministic regime, applicable to cell populations that are large
enough for statistical uctuations to be relatively small (wild-type and common mu-
tant strains). We explicitly add expressions for Poisson rates for the occurrence of rare
mutations. Using standard survival analysis, we compute, as a function of time, the
probability of avoiding a mutation event. Furthermore, we introduce an additional
72
timescale to the `survival function' to capture the time over which cells infected by an
unt genome persist before being ecologically overwhelmed. This `survival function'
is a continuous state variable that is incorporated into the system of ODEs without
much complexity.
We apply our modelling framework to clinically inspired scenarios. Firstly, we
explore the quasi steady state that corresponds to chronic treatment in the presence of
two viral populations. We characterize treatment regimes in which rates of appearance
of rare mutants are either increased or decreased. Secondly, inspired by regimens used
for PMTCT in resource limited countries, we investigate the transient behaviour of
the model under a short perturbation of the tness parameters, such as occurs during
a short course of suboptimal therapy. Transient therapy signicantly increase the
hazards of rare mutations. Thirdly, we explore the interaction between a monotherapy
short course and subsequent ongoing antiretroviral therapy (ART). Appendix D deals
with details of mutation combinatorics.
4.2 The Model
We develop a hybrid deterministic-stochastic model of healthy and infected T cell
populations. Our analysis starts with a standard multi-strain model of in-vivo viral
replication that distinguishes cells infected with one of Ns viral strains. These kinds
of models have been used to try to understand viral evolution in the context of
immune response and antiretroviral therapy [3, 5, 13, 125, 126]. For our purposes,
we add a new self-consistent stochastic element to the standard deterministic model
of viral evolution. Uninfected T cells are produced at rate ST and die at rate T:
Virus-producing cells, infected with strain i; are counted under Pi and have a mean
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lifetime of 1=P: Mass-action (perfect mixing) contact between infected and healthy
cells produces new infected cells, with a rate constant ki: The probability of error free
transcription is given by f and ij is the probability of a particular mutation, that is
strain i arising out of strain j from a reverse transcription error. This leads to the
base model equations:
dT (t)
dt
= ST   T (t)
NdX
i=1
kiPi(t)  TT (t) (4.2.1)
dPi(t)
dt
= fkiPi(t)T (t) +
NdX
j=1
j 6=i
ijkjPj(t)T (t)  PPi(t); i = 1;    ; Nd
where Nd is the number of strains which are modelled by a deterministic process,
i.e. those strains which are assumed to be present with suciently large populations
for deterministic models to be sensible. We address the incorporation of rare strains
shortly.
Physiologically, HIV transmission occurs either by cell-free viral particles released
by infected cells, or by direct cell-to-cell contact. It has been demonstrated that
cellular contacts drastically enhance productive viral transfer compared to what is
observed with free virus infection [135]. Our model, like previously published models
of in-vivo HIV dynamics, does not have free virions. Even if free virions are physio-
logically important, including them for the present purposes would not change any of
our conclusions as the dynamical eects appear only at very short time scales. In our
basic model, ki is a composite tness parameter that captures the eective cell-to-
cell transmission eciency via all mechanisms. Antiretroviral therapy with currently
known drugs does not aect virion or infected-cell survival, but interferes with some
stage of the viral replication cycle, i.e. reduces the values of the tness parameter
ki: This basic model also does not explicitly incorporate the dynamics of immune
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system response such as clonal expansion of eector cells or feedback linking viral
and infected-cell clearance rates to the healthy cell population. Our base parameter
values are given in Table 4.1.
Table 4.1: Model parameters
Symbol Description Value Source
T natural healthy cell death rate 0.02 day
 1 [11]
P productively infected cell death rate 0.5 day
 1 [24]
ST supply rate of target cells 2 108 cells day 1 Estimated
ki viral strain infectivity varies Estimated
21 single-point mutation rate 2:5 10 5 Appendix D
f probability of error free transcription 0.37 Appendix D
Since it is not possible to measure all of these parameters directly in-vivo, some of
these values are hypothetical, but they give rise to reasonable dynamics. We assume
a universal, single-point-mutation rate, where the substitution rate of any base is
of the order 10 4 [109]. The derivation of any particular ij follows directly from
combinatorial arguments outlined in the Appendix D .
Latently infected cells may be responsible for ongoing viral production in treated
individuals, and their presence will introduce a longer timescale into a model. To
capture eects of long-lived cells, we can consider the following model:
dT (t)
dt
= ST   T (t)
NdX
i=1
kiPi(t)  TT (t)
dPi(t)
dt
= fFkiPi(t)T (t) +
NdX
j=1
j 6=i
ijkjPj(t)T (t) + aLi(t)  PPi(t); i = 1;    ; Nd
dLi(t)
dt
= f(1  F )kiPi(t)T (t)  aLi(t); i = 1;    ; Nd: (4.2.2)
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Error free infected cells either become productive or latent. A fraction F of infected
cells become virus producing. The others become latent and, on average, take time
1=a to reactivate to become virus-producing cells. For simplicity, we assume that
latently infected cells have a much longer lifetime than their activation time. Note
that for F = 1; we obtain system 4.2.1. By adjusting F (it cannot be very realistically
estimated directly from data) we can vary the importance assigned to the presence of
latently infected cells, without changing the equilibrium values of healthy and virus-
producing infected cells. The model assumes that latently infected cells do not mutate
at either infection or activation and are merely infected cells with integrated provirus
that is transcriptionally silent [21, 23]. For our purposes, only a small fraction of cells
become latent therefore incorporating mutation of these cells would not signicantly
change our conclusions. We do not attempt to capture ne physiological details of
latently infected cell dynamics, but rather the concept that these cells can be the
source of new productively infected cells and hence give rise to slower dynamics than
a model with just virus producing infected cells.
Our main goal is to model rare mutation events which are characterized by waiting
times rather than continuous processes. We consider scenarios in which the initial
populations of these rare mutations are zero, and we would like to model the waiting
time to their appearance. In this regime, the appearance of rare mutant strains
i (Nd < i  Ns) should be modelled as a nonhomogenous Poisson process with
intensity
i(t) = T (t)
NdX
j=1
ijkjPj(t); for i = Nd + 1;    ; Ns; (4.2.3)
which captures mutations from all the deterministically modelled strains. (Recall
that Ns is the total number of strains.) According to standard survival analysis, the
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probability of there being no rare mutant of type i, at time t; given that there was
none at time 0, is
i(t) = exp

 
Z t
0
i()d

: (4.2.4)
The phylogenetic relationships amongst all strains, and the initial conditions, deter-
mine the number of continuously and stochastically modelled strains. We adopt the
following computational procedure:
1. Initially run the deterministic model with populations for Nd strains, and sur-
vival functions for avoiding the Ns  Nd rare mutants.
2. Draw a uniformly distributed random variable Ri 2 [0; 1] for each possible rare
mutation event.
3. When i reaches Ri the appearance of mutant i occurs.
4. If the mutant appears into an environment in which it is t enough to thrive,
pause the simulation.
5. Add one cell of the new rare mutant.
6. Resume running the new deterministic model with N 0d = Nd + 1 strains.
This piecewise deterministic model is hardly more complex than a purely deterministic
model. The abrupt changes to the evolving process transforms the ODE system
into dierential equations involving impulse eects (impulsive dierential equations)
[78]. The dierence between our computational approach and previously considered
schemes of which we are aware, is that in our scheme, mutation hazards are derived
from explicit deterministic model state variables, and also, they depend on mutational
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pathways, whereas, for example, in Nowak et al [111], the probability of generating
a new mutant is proportional to the total virus population.
Note that in the computational procedure just outlined, we have only explicitly
modelled the consequences of those rare genomes which have a tness above a crit-
ical value. Of course, the appearance of low tness mutations is also possible. We
now propose that genomes with sub-critical tness, which do not give rise to explic-
itly modelled populations, survive, presumably in trace quantities, for a typical time
(which we call ) before they are driven to extinction. If there is an environmental
shift during this persistence period, such as initiation of therapy that strongly sup-
presses the other genomes, this one can then begin to thrive and grow in the same
manner as any mutation which arises into an initially favourable environment. If the
perfect-mixing model is assumed to be valid on all size scales, this new timescale
would simply be the lifetime of the infected cell bearing the new genome, as an unt
variant will be unlikely, under a fully stochastic treatment, to produce daughter cells.
However, it is far from certain that this simple view captures the dynamics surround-
ing rare mutations. A small local cluster of cells bearing the new genome may have
a good chance of arising from the seminal mutation, but then be almost certain to
be overwhelmed ecologically within a typical time as mixing or directly competing
with tter variants occurs. Since we do not know what this time may be, we simply
note the crucial role it plays in our modied survival analysis. Now, instead of simply
considering the probability that the mutant has never occurred since time 0, as in
equation 4.2.4, we consider the probability that a rare mutant has not occurred in
the most recent time interval of size , i.e.
(t) = exp

 
Z t
t 
()d

: (4.2.5)
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This new state variable is just the probability that the relevant mutant genome is
absent at time t. The smallest physically feasible value of  is the lifetime of an
infected cell (as noted above for the case where the rare mutant produces no daughter
cells from the seminal mutation) and the largest feasible value is greater than the
expected survival time of the infected individual (if the genome is signicantly banked
into a latently infected cell population) i.e. essentially innite for practical purposes.
It is particularly relevant when we model environmental shifts, such as the start or
end of an antiretroviral (ARV) regimen. We will demonstrate scenarios in which
the presence or absence of a `currently unt' genome, at the moment of initiation of
therapy, can have an impact on rates of treatment failure.
4.3 Chronic Treatment
We now apply, to clinically inspired scenarios, the survival analysis of the model pre-
sented in the previous section. The particular model implementations are in certain
respects simplistic preliminary work, but they demonstrate the kinds of questions
that can be seriously investigated within this framework. We use a model with two
continuously variable strains (wild-type and common mutant) and a waiting time
for the appearance of the third strain (rare mutant). In the absence of treatment,
the wild-type strain is dominant and the mutant subpopulation is present in trace
quantities, of the order of the mutation rate.
We are interested in modelling mutations that occur rarely i.e. those that do
not typically exist at most points in time. Consider a mutant which diers from the
wild-type by three single-point mutations (say M1, M2 and M3) and from a common
mutant (M1) by two-point mutations (M2 and M3). We assume that strains bearing
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just M2 or M3, or any two of M1, M2 and M3 are highly tness compromised i.e. the
M1 M2 M3 (P3) are all compensatory mutations. We use this particular phylogeny
to illustrate the application of our method. Adding a rare mutant to a two-strain
deterministic model as strain i = 3 gives the Poisson rate
3(t) = T (t)

31k1P1(t) + 32k2P2(t)

; (4.3.1)
which shows how a rare mutant variant can arise through a number of pathways, such
as sequential single-point mutations or simultaneous higher-order mutations.
First, we consider a quasi steady state scenario corresponding to chronic treat-
ment, then we model a short course of monotherapy, followed, after some delay, by
initiation of chronic therapy. Important interactions between the two regimens are
captured by the newly introduced state variable .
We start by analyzing the steady-state dynamics of the two continuously modelled
strains in the absence of a rare mutant. The choice of parameter F , which introduces
latently infected cells, does not aect this analysis. An approximate, much simpler,
equilibrium solution can be derived directly from the exact equations 2.1.9 by setting
221 and other higher-order terms to zero, where  is replaced by 21:
T =
P
fk1
+O(221)
P1 =
T
k1
(R001   1)

1  21k2
f(k1   k2)

+O(221) (4.3.2)
P2 =
21T
f(k1   k2)(R
0
01   1) +O(221);
where the wild-type is the tter strain (k1 > k2): The basic reproductive ratio of
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strain i is given by
R00i =
fSTki
PT
i = 1; 2: (4.3.3)
We are interested in modelling the regime where R00i is always greater than one in the
absence of therapy, since our main focus is on persistent infection. Note that
P2 =
21k1
f(k1   k2)
P1 +O(
2
21): (4.3.4)
The less-t strain is present in trace quantities that will be very dicult to detect by
standard clinical assays, even if the tness dierence is marginal. This is a modied
version of the usual population genetics phenomenon that two species in a single niche
do not coexist even with very similar tness; one dominates and drives the other to
extinction. The non-extinction of the less-t quasispecies observed in this case results
from the high mutation rate, which leads to waiting times between mutation events
that are very small compared to the lifetimes of productively infected cells, so that
the subdominant species persists in signicant quantities. Given realistic orders of
magnitude for infected cell populations (108) and lifetimes (a day), and the mutation
rates between strains that dier by a single base mutation (10 5) [24, 55], certain
minority populations (single-point and double-point mutations relative to a dominant
wild type) are large enough to be modelled deterministically.
The mean waiting time to the occurrence of a rare mutation according to the Pois-
son rate (equation 4.3.1) before treatment (evaluated at the pre-treatment equilibrium
state) is given by
hwi =
"
T

31k1 P1 + 32k2 P2
# 1

"
ST(R
0
01   1)
R001

31 +
(32   31)21k2
f(k1   k2)
# 1
:
(4.3.5)
It is important to understand how fundamentally dierent this result (and reality)
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is from a what can be obtained in a model which treats all strains deterministically.
Mathematically, it is perfectly sensible to dene a model with any number of deter-
ministically strains, as per the basic model above, and to try to capture the `rare'
mutants by using suitably small mutation rates. When a purely deterministic model
runs from an initial condition in which the tter strain is absent, this absent strain is
immediately produced continuously. The new strain then grows according to its t-
ness advantage (see gure 4.1). Thus, the time taken for it to reach some proportion
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Figure 4.1: Growth of a rare mutant strain (i.e. with no waiting time) in the deter-
ministic model. The initial value of the rare mutant (P3) is zero whereas viral strains:
wild-type (P1) and common mutant (P2) begin their dynamics from the steady state.
The rare mutant is immediately produced continuously and grows according to its
tness advantage. The time required to attain one cell infected by this rare mutant
is of the order of weeks. In these simulations, the dierential tness parameters are
given by (k3; k2; k1) = (2k1; 0:9k1; k1) where k1 = 2  10 8; that is, the environment
favours the rare mutant to outgrow existing viral variants.
of the total infected cell population is deterministic, and substantially dominated by
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the dynamical interaction of the two strains. The time required to attain one cell
infected by the new strain (P3 = 1) can be derived by solving P3(t) = 1 from an
initial value of P3(0) = 0, and using the dynamical equation
dP3(t)
dt
= fk3P3(t)T (t) + T (t)

31k1P1(t) + 32k2P2(t)

  PP3(t)
= ~3 + P(   1)P3(t) (4.3.6)
where
~3 =
ST(R
0
01   1)
R001

31 +
(32   31)21k2
f(k1   k2)

and  =
k3
k1
> 1: (4.3.7)
This implements the assumption that the other cell populations are not signicantly
perturbed from their initial values over the time it takes to produce one cell of the
rare mutant. Then
h1i = 1
P(   1)ln

1 +
P(   1)
~3

: (4.3.8)
For the chosen parameter values (Table 4.1), the time required to attain one cell
infected by the new strain is of the order of weeks (see gure 1). On the other
hand, the explicitly modelled mean waiting time (hwi) to the occurrence of the new
mutation according to the constant Poisson rate ~3 is of the order of years. It seems to
us that the latter is a reasonable model of rare events and the former is fundamentally
awed.
We now return to the stochastic waiting time model, which at the pre-treatment
equilibrium state, has a waiting time to the occurrence of a rare mutant of the order
of years for the chosen parameter values given in Table 4.1. We are interested in
the impact of long term treatment on these waiting times. Let treatment ecacy on
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strain i be denoted by i 2 [0; 1], so that the infectivity parameter during treatment is
k0i = iki. In gures 4.2 and 4.3, we show the surface plots of the waiting times to the
occurrence of rare events as a function of drug ecacy on viral strains. Less eective
selection pressure or treatment that successfully suppresses both viral subpopulations
results in increased waiting times or even guarantees the non-occurrence of rare mu-
tations. Suboptimal treatment that suppresses the wild-type strain but barely aects
the common mutant leads to dramatic reduction in waiting times to the occurrence
of rare mutations. On the other hand, treatment that aects the common mutant
but allows continuation of wild-type strain replication, increases the waiting time to
the occurrence of a rare mutant.
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Figure 4.2: Surface plot showing the waiting times to the occurrence of rare mutations
as a function of drug ecacy on viral strains (i) for k2 = 0:9k1 where k1 = 2 
10 8: The point ((1; 2) = (0; 0)) represents potent treatment that results in viral
elimination.
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Figure 4.3: Surface plot showing the waiting times to the occurrence of rare mutations
as a function of drug ecacy on viral strains (i) for k2 = 0:1k1 where k1 = 2 
10 8: The point ((1; 2) = (0; 0)) represents potent treatment that results in viral
elimination.
A key result is that waiting times are signicantly smaller when the common
mutant is only marginally less t, than when there is a large tness cost. Note that
these plots describe a relationship between `clinical' parameters (waiting times) and
pharmacological parameters (drug ecacies) which are dicult to determine in-vivo.
On the other hand, quantitation of plasma HIV RNA can be performed to determine
viral populations which in turn can be used as alternative parameters to calculate
the waiting times to the occurrence of rare mutations. We demonstrate this by
introducing parameters which express treatment eectiveness at the level of changes
in the equilibrium viral loads. Let the treated equilibrium values of the wild-type and
the mutant-strain-infected cell populations, relative to the pre-treatment wild-type
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infected cell level, be given by
Fw =
P1(k
0
1; k
0
2)
P1(k1; k2)
and Fm =
P2(k
0
1; k
0
2)
P1(k1; k2)
; (4.3.9)
respectively. Recalling that in the untreated state, the viral load is strongly dominated
by the wild type ( P1(k1; k2)), this notation facilitates comparisons between the treated
and untreated states, both in terms of overall viral suppression, and selection between
strains.
Disruption of the pre-treatment equilibrium state (Fw = 1 and Fm  1) by
therapy leads to dierent possible eects on the \benchmark" (pre-treatment) waiting
time. The limiting case scenarios of interest are
1. Therapy suppresses the mutant subpopulation (Fm ! 0) but allows the domi-
nant wild-type strain to replicate relatively unhindered (Fw  1); this increases
the waiting times to the occurrence of a new strain. In other words, even though
the total viral load is barely aected, there is a benet in terms of impaired viral
evolution.
2. Treatment is optimal against the wild-type strain (Fw ! 0) but barely aects
the common mutant i.e.
Fm ! k1
k2

R002   1
R001   1

; (4.3.10)
where R00i is strain i reproductive ratio. This leads to a dramatic reduction in
waiting times to the appearance of rare mutations, i.e. the much more rapid
emergence of the rare mutant.
3. Treatment is optimal; that is, treatment that successfully suppresses both vi-
ral subpopulations ((Fw; Fm) ! (0; 0)). This essentially guarantees the non-
occurrence of rare mutations.
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4.4 Transient Nevirapine Monotherapy
We use our piecewise deterministic model to explore the consequences of transient
increases in the relative frequency of common mutations (such as K103N) on the
occurrence of rarer mutations, during and after short-course monotherapy. To obtain
curves resembling the K103N decay data shown in gure 4.4 [90], we incorporate a
population of latently infected (i.e. long-lived and non-virus-producing) cells [22, 115]
that are activated to productively infected cells on a timescale of 2 to 3 weeks, by
setting F = 0:9:
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Figure 4.4: Relative fractions of K103N variants in maternal plasma viral RNA after
single dose nevirapine for three individual women (NVP16, NVP19 and NVP196).
We read data o a chart published in [90]. In this study, the relative abundance of
K103N declined to undetectable levels by 12 months [90]
First we explore the eect of a single short course of highly selective treatment
on waiting times to the appearance of rare mutations. Initiating suboptimal therapy
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results in dramatic increase of the common resistant mutant (K103N) population
and an equally dramatic decrease in the wild-type strain (K103) population. When
pressure of therapy is discontinued, the common mutant population declines to pre-
treatment levels. At every time point during and after short course therapy, we
evaluate the cumulative probability of a rare mutation having occurred. Figure 4.5
illustrates the transient increase and decline in the proportion of a common mutant,
and gure 4.6 shows the corresponding cumulative probabilities of observing a rare
mutant. We compare the cumulative probability under transient treatment to the
case in which therapy is not given at all. For the chosen parameters, the probability
of observing a rare mutation, within a year in the absence of therapy, is negligible.
However, transient therapy dramatically increases this probability.
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Figure 4.5: Relative frequency of K103N during and after 7 days of idealized treat-
ment. Short-course highly selective therapy results in dramatic increases in pre-
existing resistant viral variants. Withdrawal of therapy results in a slow decline of
the subpopulation. We assume that 10% of infected cells become long-lived infected
cells and are activated after 2 weeks i.e. we set F = 0:90 and a = 1=14:
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Figure 4.6: The cumulative probabilities of observing a new mutation in the ab-
sence (Equilibrium) and presence (Transient) of drug pressure. Model choices which
produce a transient of a magnitude and duration shown in gure 4.5 lead to signif-
icant acceleration of viral evolution. In the absence of selective pressure chances of
observing a new mutant are negligible.
Next we explore the interaction between a monotherapy short course and subse-
quent continuous therapy, as was investigated in the MASHI study. We evaluate the
probability that a rare mutant is currently present at time t, given various possible
values of the rare mutant persistence timescale  (see gure 4.7). For values of  less
than 60 days, the probability of a rare mutant being present, at some point more than
6 months after the single dose of NVP, is small (< 5%) i.e. cells infected by the new
genome are unlikely to be present, and hence pose a low residual risk if the mother
is put on treatment more than six months after single dose Nevirapine for PMTCT.
This is not inconsistent with the clinical ndings from the MASHI study [88]. The
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reality is presumably more complex than what our model can capture, but little is
known about the persistence of unt mutants. It has been observed that resistant
genomes may persists, even at undetectable level, for prolonged periods [17, 35]. It
makes sense that initiating therapy in the presence of a therapy defeating mutant,
or an immediate precursor to such a mutant (even at levels too low for detection by
typical assays), will reduce chances for treatment success.
0 10 20 30 40 50
0
0.2
0.4
0.6
0.8
1
Weeks
P
ro
ba
bi
lit
y 
th
at
 a
 m
ut
an
t i
s 
pr
es
en
t
 
 
∆=2
∆=15
∆=30
∆=60
∆=120
∆=∞
Figure 4.7: The probability of there existing a mutant which persists for a time 
after a seminal mutation, plotted as a function of time from a brief period of selective
pressure (such as single dose NVP). Plots are shown for a number of values  ranging
from 2 days to 350 (taken as 1) days. The other parameter values are as in gure
4.5.
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4.5 Conclusion
We have considered a number of more-or-less standard deterministic multi-strain mod-
els of in-vivo viral dynamics, which are tunable to produce scenarios like a chronic
ARV regimen, and a short course of monotherapy. We have adjoined a stochastic
component to these models, in the form of a 'sliding window' survival analysis, which
substantially expands the possible analyses of rare strain dynamics within the frame-
work of ordinary dierential equations.
We have considered scenarios which capture the concepts of a dominant wild-type
strain, a relatively unimpaired 1 base mutant, a number of unviable 2 base mutants,
and the possibility of compensatory mutations which lead to a treatment defeating
3 base mutant that is reachable by dierent pathways, which have dierent relative
importance at various stages during transient dynamics. Dierent phylogenies, to-
gether with dierent chosen tness parameter values, will result in dierent numbers
of deterministically and stochastically modelled strains and pathways, all of which
can immediately be accommodated into our general model.
The transient increases in common subpopulations of cells infected by mutant
genomes produced by the short course of antiviral therapy aects waiting times to
the appearance of rare mutations, conceived as diering more from the wild type than
from the deterministically modelled primary mutant. Over a range of model choices
which produce a transient of the order (size and duration) of that known to occur
under nevirapine monotherapy used for PMTCT, there is signicant acceleration of
viral evolution - even from just the short course alone. This eect is suspected, but
not unambiguously observed, from clinical studies.
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A further important set of questions arises about the risks associated with ini-
tiation of chronic therapy (HAART) a short while after the suboptimal transient
regimen like for PMTCT. Our newly proposed additional timescale , representing
the persistence of a new genome in an infavourable environment has a substantial
impact on the rates of treatment failure.
These models demonstrate that even transient subpopulations of common mutants
which appear to fade are associated with accelerated appearance of rarer mutations.
Further work which should be performed includes 1) variations on these models which
are designed to capture precise genetic dierences (and hence realistic pathways and
mutation rates) between sets of quasispecies being directly observed in studies utilis-
ing highly sensitive assays, and 2) biological investigation into the dynamics of small
populations of new mutants (the theme of chapter 5), which these models summarise
into the timescale .
4.6 Summary of Implications for Public Health
Results in this chapter show that even relatively brief, and fully reversed, increases
in subpopulations of common mutants are associated with accelerated appearance of
further rarer mutations. The accelerated appearance of new genomes in patients on
failing therapy highlights a potential risk for public health. The analysis highlights
an important point of biology which is dicult to observe, and on which experimental
evidence would be instructive. Specically, it is likely that rare mutations carrying
potentially serious properties like multiple drug resistance occur from time to time,
but that these variants are created largely in unfavourable environments where they
do not thrive, so that they usually become extinct in a short time. Knowledge of
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how long these transient subpopulations of new genomes persist would help guide
expectations for studies trying to link patterns of treatment, viral load, etc. to longer
term outcomes like regimen failure. These issues will need to be investigated in the
long run as more and more clinicians and their patients face complex decisions about
regimen choice and switch.
Chapter 5
Modelling the Persistence of Drug
Resistant Mutations After
Cessation of Suboptimal Therapy
5.1 Introduction
This chapter reects on how the the previous chapter might be extended. In chap-
ter 4, we showed how suboptimal therapy may accelerate the appearance of higher
order rarer mutations. However, we did not investigate in a dynamically consistent
way whether the new cell harboring the rare mutant will die before infecting other
cells or before infecting enough other cells for it to be xed, i.e. the persistence of
mutants. The absolute time it takes for subcritical minority variants to eventually go
to extinction is not known. Initiating therapy in the presence of a therapy defeating
mutant, even at levels too low for detection by typical assays, will reduce chances
for treatment success. Since we do not know what this time may be, in the previous
chapter, we simply noted the crucial role it plays in the modied survival analysis. In
reality, the new rare mutant has to compete with existing strains, i.e. its persistence
depends on its characteristics such as viability and replication ability.
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In clinical practice, resistance tests are performed at baseline and also on patients
who are failing therapy. However, there is a big danger of misinterpreting resistance
tests, due to failure in minority mutation detection, such that clinicians may end up
administering regimens that may fail to suppress viremia. In treatment naive patients,
mutations that are not detected at baseline may subsequently emerge during the early
weeks of therapy [102]. In patients on failing regimens, newly emergent mutations
may not be detected because they may not replicate to levels that are detectable.
Administering therapy in the presence of these undetectable minority species increases
the risk of continued selective pressure which may result in development of additional
mutations.
The persistence of transmitted or primary drug resistance has been assessed
[10, 15, 29, 43, 85, 119] and results have shown that primary resistance persists over
a prolonged time-period even in cases where mutants have impaired replicative com-
petence. Secondary resistance (developed in response to antiretroviral treatment) is
usually lost at a rapid rate [10]. However, little is known about typical persistence
times of these small populations.
Here, we investigate the persistence of secondary resistance that develops after
a short course treatment. We perform numerical simulations of the hybrid model
developed in the previous chapter. Our framework allows us to assess the role of
stochasticity and its interplay with nonlinearity. This framework is appropriate for
modelling small populations as ODEs cannot incorporate high heterogeneity, because
small populations become important and important events become random. To better
understand the relationship between tness cost and persistence times, we vary the
new genome's replicative ability and determine the likelihood of persistence of this
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new genome lineage in the face of competition from existing strains after its initial
appearance. The replacement or mutual co-existence of strains is strongly inuenced
by competition. The only form of competition in our model is the infection of healthy
target T cells.
5.2 The Model
From the deterministic model developed in chapter 4 given by system of equations
4.2.2, we can derive a full stochastic model, i.e. a Markov jump process. The schema
for this process, which species the probability of the system transitioning to each of
the possible states, is given in Table 5.1. Recall that the model assumes, for simplicity,
that latently infected cells do not mutate at either infection or activation and are
merely infected cells with integrated provirus that is transcriptionally silent [21, 23].
The sojourn times in each state of the process follow an exponential distribution, thus
stochastic events are timed by an exponential clock with a parameter

 =
X
Jumps
(Rate) ;
= ST + TT +
NsX
i=1

fkiPiT + PPi + aLi

+
NsX
i=1
j 6=i
jikiPiT; (5.2.1)
a sum of all allowed jump rates (see Table 5.1). This parameter is an average of an
exponential distribution and is used to generate the next jump time. Also, the type
of the next jump is random in this stochastic process. Assuming that both jumps and
jump times are random is convenient because even in theory we don't know when the
next event (e.g. infection of a target cell, death of an infected or uninfected cell, etc)
will occur, nor even what it will be.
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Table 5.1: Stochastic process schema showing allowed jumps and jump rates
Event Jump Rate
Supply of target T cells T ! T + 1 ST
Target T cell death T ! T   1 TT
Infection of T cells by strain i :
(a) error free transcription :
(i) productive infection T ! T   1 and fFkiPiT
Pi ! Pi + 1
(ii) latent infection T ! T   1 and f(1  F )kiPiT
Li ! Li + 1
(b) mutation into strain j (for j 6= i) T ! T   1 and jikiPiT
Pj ! Pj + 1
Activation of strain i latently infected cell Li ! Li   1 and aLi
Pi ! Pi + 1
Strain i productively infected cell death Pi ! Pi   1 PPi
One standard way of analyzing this problem is to use Gillespie's algorithm [45] but
because some of our processes involve large numbers (billions of cells), this method
becomes inecient as it searches for the next event (maybe in less than a nanoday)
[72, 149]. Although ecient methods have been developed that involve either grouping
together processes that occur in fast succession ( - leap methods) [16, 46, 123],
application of quasi-steady-state theory [122], or averaging over rst reactions [60],
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purely stochastic simulations of such systems remain computationally expensive.
We adopt a strategy that models processes with a large number of cells (fast
rates) in a deterministic way whilst keeping small populations as stochastic processes
(i.e. minority populations become random). Mixed frameworks have been proposed
to simulate biochemical systems [2, 54, 73, 138, 147]. They are mainly based on a
prediction correction type heuristics for the realization of the stochastic part. The
main concept is to rst calculate the time (waiting time) in which a stochastic event
should occur. During the waiting time to the next jump, the ODE component of the
process is kept evolving [2]. Our populations are divided into compartments. Small
populations evolve in a discrete compartment and we call this compartment D whilst
large populations are in a continuous compartment called C simulated by ODEs, i.e.
our compartments are:
fT; P1; P2; L1; L2g 2 C and fP3; L3g 2 D:
In our mixed method, the dynamics of healthy T cells, wild-type and common
mutant infected cells is given by the sum of all fast rates or simply by a set of
ODEs given in chapter 4 (equation 4.2.2) whilst the stochastic schema for the discrete
populations P3 and L3 is given in Table 5.2. We write the mutations' tness parameter
as ki = (1   fi)k1 for i = 2; 3 and f2; f3 are tness costs for the common and rare
mutant, respectively. To simulate our system, we use the direct hybrid method [2].
This method explicitly calculates which event occurs next and when it occurs. At the
beginning, the system is set to the initial state. An exponential random number with
a mean of one is drawn to prepare for the numerical integration of the ODE system.
The time to a discrete event is determined by the cumulative hazard function that
depends on the state of the system. If a discrete event has been generated, the next
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event to occur is randomly chosen and the state variables are updated accordingly.
This procedure continues until the entire trajectory is computed. The pseudo-code is
given in Appendix E.
Table 5.2: Stochastic process schema showing allowed jumps and jump rates for small
populations (or for slow rates)
Event Jump Rate
Infection of T cells by strain i :
(a) error free transcription :
(i) productive infection T ! T   1 and fFk3P3T
P3 ! P3 + 1
(ii) latent infection T ! T   1 and f(1  F )k3P3T
L3 ! L3 + 1
(b) mutation into strain P3 (i = 1; 2) T ! T   1 and 3ikiPiT
P3 ! P3 + 1
Activation of latently infected cell L3 ! L3   1 and aL3
P3 ! P3 + 1
Productively infected cell death P3 ! P3   1 PP3
We have explained in principle how hybrid simulations can be done (an example
is given in the next section). To determine approximately persistence of new genomes
does not require explicit modelling of the stochastic process of population eradication.
We now demonstrate that, in practice, population numbers for infected cells are
typically large enough to be modelled deterministically for heuristic conclusions about
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magnitudes of persistence times, i.e. \deterministic extinction". A scenario in which
we can model stochastic persistence explicitly is the radioactive decay process. We
assume that a constant per-item decay rate is given by the parameter ; and we
calculate the mean time it takes to reach 0 items, starting from an initial population
of P: This mean decay time is given by
E[0] =
1

PX
n=1
1
n
:
We can calculate the number of cells at E[0]; in the deterministic version of the
model, as
P (E[0]) = Pe E[0]: (5.2.2)
The coecient of variation (the ratio of the standard deviation to the mean) is cal-
culated as:
cv =
p
var
E[0]
; (5.2.3)
where the numerator is the standard deviation (square root of the variance). The
variance of the decay time is given by:
var =
1
2
PX
n=1
1
n2
:
We show the dependence of the expected number of cells at the expected time to
decline to zero and the coecient of variation with the initial population size in gure
5.1. The number of cells evaluated at the expected decay time rapidly approaches
an asymptote with a value close to one half and the coecient of variation, for a
population that starts at a size of at least 100 is somewhat less than 20%, but declines
slowly with initial population size. Evidently, the intrinsic uncertainty in persistence
in the stochastic process dominates over any error made in using the deterministic
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model to estimate expectation values. In this example, it was not dicult to calculate
the stochastic result, but in the HIV applications which follow, there is not a single
decay rate, so the fully stochastic model is considerably more complex. We will model
a fading subpopulation deterministically.
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Figure 5.1: A: The number of cells at the expected decay time, i.e. \deterministic
extinction". B:The coecient of variation as a function of the initial population size.
5.3 Persistence of Rare Mutations
First, we present simulations of the hybrid model that resemble the single dose NVP
case presented in chapter 4, where we have assumed a 10% tness cost (f2 = 0:1)
for the common mutant strain and a 5% tness cost (f3 = 0:05) for the rare mutant
that appears as a result of suboptimal suppression. The dynamics of all populations
started from an infected equilibrium state with two strains (see equation 2.1.9) are
shown in gure 5.2. We assume treatment is administered for 7 days. For these
parameter values, the mean time to appearance of a rare mutant is 0:54  0:005
weeks (with a probability of appearance within a year of 0.9998 after 104 runs).
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Figure 5.2: A single realization showing the dynamics of infected cell populations
for a scenario such as NVP given previously. A: uninfected T cells, B: productively
infected cells, C: latently infected cells and D: proportion of P2 cells. Here f2 = 0:1;
f3 = 0:05; k1 = 2  10 8; we assumed 7 days of idealized treatment and simulations
are started at the two strain equilibrium state.
Now we investigate the typical time until a small cluster of cells infected by the new
genome persist before disappearing. Using the survival function for the appearance
of a rare mutant given by equation 4.2.4 (see gure 5.3(A)), we can calculate the
distribution of times to rst occurrence of a rare mutant, i.e. the probability that a
rare mutant rst appears in any interval [a b] is given by (a) (b): For short term
treatment, we calculate the probability that a rare mutant will appear in sub-intervals
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between 0 and 7 days. These intervals for the time to rst appearance of the rare
mutant are broken down as in Table 5.3. A new rare genome with a subcritical tness
cost that appears in the absence of selective pressure persists for a while or even make
occasional ospring and nally go to extinction. We want to assess persistence time
of subcritical genomes that appear, survive for a short time in the presence of pressure
that favours them and then go to extinction after the removal of selective pressure.
Table 5.3: The probability that a new rare mutant will appear in a given interval,
using the survival function given by equation 4.2.4.
Interval [0 1] [1.01 2] [2.01 3] [3.01 4] [4.01 5] [5.01 6] [6.01 7] [ 7.01]
prob (%) 0.02 0.11 1.84 19.24 11.35 5.21 4.65 57.58
In gure 5.3(B), we show the dynamics of wild-type, common mutant and rare
mutant infected cells. We assume that prior to treatment we have only two strains
(wild-type and common mutant) and after starting treatment, the new genome (rare
mutant) appears after 0.5 days. Recall that the new genome is only rare in the
absence of suboptimal therapy. In this case, the new genome carries a 10% tness cost
relative to the wild-type strain. Under drug inuence the environment is favourable
for the rare mutant (it is tter than the wild-type strain) so it grows to fairly large
populations such that we can use the deterministic model to compute \deterministic
extinction" times. In this scenario, the appearance of the rare mutant is stochastic
and its growth and decay are treated deterministically.
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Figure 5.3: A: Survival function, (t); up to 350 days and B: The dynamics of all
infected cell populations (wild-type (P1), common mutant (P2) and rare mutant (P3))
when treatment is administered for 7 days. Here f2 = f3 = 0:1; k1 = 2  10 8; and
simulations are started at the two strain equilibrium state. The rare mutant is allowed
to appear after 0.5 days.
Now we vary the replicative disadvantage of the new genome and time of appear-
ance and assess the typical time it takes to decay to a single cell. In our simulations,
we introduce a new rare mutant at the middle of each interval and allow it to grow
deterministically and assess the time it takes for its population to reach a single cell
(\deterministic extinction" time). Now, we can ask questions such as: what is the
probability that a cluster of cells infected by the new genome exist in the population
at 6, 12 and 18 months for varying tness cost parameter?
For illustration purposes, we assume that a rare genome carries either a 5%, 10%
or 50% tness cost relative to the wild-type strain. For each of these replicative
competencies, we assess the persistence of the new genome that appears at the centre
of these intervals [0 1], [1.01 2], [2.01 3], [3.01 4] and [4.01 5]. We let the rare mutant
population size decline to a value near one, see gure 5.4 which shows the dynamics of
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the rare mutant infected cell population. Through eye-balling, we note the population
size of rare mutant infected cells at dierent time points (6, 12 and 18 months for our
scenario) after suboptimal treatment and determine persistence through stochastic
averaging over initial conditions, i.e. use the probability distribution of appearance
given by the intervals (see Table 5.3) to evaluate the likelihood of persistence, see
Table 5.4.
After 18 months, only mutants that emerge at the centre of either intervals [0 1]
or [1.01 2] (and if the mutants carry a 5% tness cost relative to the wild-type strain)
will be still present in the population. Thus the probability that a rare mutant with
a 5% tness cost will exist after 18 months is approximately given by 0.1%, which is
calculated from the sum of respective probabilities of appearance in intervals [0 1] and
[1.01 2], i.e. 0.02% + 0.11% rounded o to 1 decimal point. Similarly, assuming a rare
mutant with a 10% tness cost, there is a 2% probability that it will persist beyond
6 months (since genomes that appear at the centre of three intervals [0 1], [1.01 2]
and [2.01 3] will be still present). A new genome with a 50% growth disadvantage is
guaranteed to die out quickly.
From this ad hoc approach of using initial stochastic conditions to predict intrinsic
population decay rates, i.e. extinction probabilities, we observe that there is a compli-
cated relationship between persistence time and the time at which the new genomes
appear. Small population persistence is determined by both replication competence
and the environment.
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Figure 5.4: Dynamics of the rare mutant with 5%, 10% and 50% 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to the wild-type strain that gets produced at the centre of the intervals [0 1], [1.01
2], [2.01 3], [3.01 4] and [4.01 5]. The other parameter values are as in gure 5.2.
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Table 5.4: The probability that rare mutant infected cells exist at 6, 12 and 18 months
as a function of growth disadvantage and time of occurrence (these are approximate
values).
Rare mutant tness cost(f3) 6 months 12 months 18 months
0.05 21% 2% 0.1%
0.10 2% 0% 0%
0.50 0% 0% 0%
5.4 Conclusion
Numerical simulations of the hybrid model conrm the signicant acceleration of viral
evolution from just the short course treatment. We have performed full simulations
incorporating assumptions on the replicative competence of the new genome to assess
persistence of secondary resistance after short course treatment. Varying the rare
genome's replicative ability and the time to appearance, we have determined the
period at which the new genome lineage will be sustained in the face of competition
from existing strains after the initial appearance of a single cell with a new genome.
In terms of the interaction between a short course and subsequent continuous
therapy, model results have shown that the disappearance of a rare mutant carry-
ing a 10% tness cost or more relative to the founder at some point more than 6
months after selective therapy is highly likely (there is a 2% likelihood of persis-
tence for rare genomes with such replicative competence). This is comparable to the
small probabilities of a rare mutant being present derived using the modied survival
analysis previously. Administering therapy in the presence of these undetectable mi-
nority species increases the risk of continued selective pressure which may result in
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development of additional mutations.
These results are also important in the setting of HIV-1 suboptimal chronic treat-
ment. It is not known whether the benets of continued treatment with a failing
regimen outweigh those of interrupting failing therapy. Maintaining suboptimal treat-
ment may have immunological and virological benets, e.g. stable immune cells and
viral load despite limited control of viral replication [28, 104]. However, long term
exposure to incomplete viral suppression may lead to the development of additional
mutations and continued exposure to drug toxicities [91, 104]. There may be benets
of discontinuing failing therapy in spite of viral rebound, such as loss of resistance
mutations [28, 66, 95]. Some studies on patients with previous treatment failures and
multidrug-resistant virus indicated that in some patients a shift to complete wild-type
population may occur upon discontinuation of all treatments [30] and that treatment
re-initiation in patients who had interrupted treatment may achieve durable virus
population suppression [27, 104]. In patients failing rst line regimens, it may be
benecial to give drug holidays before administering a second line or salvage regimen
to allow the minority variants to eventually die out.
In our models, the only form of competition is infection of target cells. It re-
mains to be seen if this form of competition alone is sucient to block or enable the
formation of quasi-species. Another issue is whether the evolution of new genomes
is a function of population sizes of existing strains alone or is due to intrinsic ran-
domness in retroviral reproduction caused by the varying activation of target cells or
both. However, as a starting point, our framework is heuristically sensible, it demon-
strates the interplay of deterministic evolution with stochastic averaging over initial
conditions.
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5.5 Summary of Implications for Public Health
It is very dicult, or impossible, to observe small subpopulations of virions and
infected cells by standard laboratory assays, so there is little direct data on these
populations. Mathematical modelling, after making particular assumptions, may be
the only recourse available to develop intuition on the dynamics of these undetectable
populations. This might not yield precise estimates but at least qualitative results
such as distinguishing fast from slow decay rates of subpopulations with no selective
advantage. The analysis in this work shows that there is a complex relationship
between occurrence time and persistence of new variants. We might not have obtained
credible estimates of persistence times but the model shows that subcritical genomes
have a high chance of going to extinction. Clinical studies of molecular evolution
guided by modelling of this kind may shed light on how best to manage patients seen
to be on failing regimens, helping shed light on such options as quick switching, what
regimen to switch to, whether to have drug holidays between regimens, or perhaps
even interim regimens.
Chapter 6
Conclusion
In this chapter, we take stock of what we have achieved in this thesis and suggest
areas of extension. The aims of the thesis were to develop and test appropriate
models of viral evolution, and then use these models to investigate the impact of
acute infection dynamics on the accumulation of mutations, the eect of suboptimal
therapy on the appearance of rare higher order mutations and the persistence of new
variants after suboptimal treatment. We tried to ensure that the models remain close
to the biology, so that the models will be fairly transparent and comprehensible to
experimentalists. On the other hand, a \kitchen sink", approach where just about
every known physiological or immunological detail is incorporated, was avoided, since
the aim was to gain some insight into overall system behaviours.
6.1 The Results
We demonstrated that while ODE models may be adequate for modelling mutations
of HIV as some variants may be produced many times a day, they are inappropriate
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to model the generation of rare mutants, as they have no explicit waiting time to the
occurrence of rare mutants. The sequence evolution framework developed by Lee et
al.[79] was successful in assessing the degree of viral diversity during the early phase of
infection. However the eect of assumptions such as dierential tness and selection
pressure can signicantly aect the overall conclusions. Viral diversity measures are
important as they can act as signals of epidemiological and clinical outcomes. We
suggest that diversity indicators that correlate to prognosis need to be sought in
experiments and clinical trials.
Transient eects of therapeutic interventions early in infection, that confer a tness
cost to early viruses, can signicantly reduce the extent of diversity later during the
chronic state of infection. This stands in contrast to the concern that early selective
pressure may increase the probability of later existence of drug resistance mutations,
for example. These models may be useful to illustrate the impact of vaccines and
PrEP on viral evolution in the case of breakthrough infection.
Scenarios with a transient change in relative tness of strains, of a magnitude
and duration such as is known to occur under NVP monotherapy, exhibit signi-
cantly accelerated viral evolution compared to no-treatment scenarios. Total viral
load suppression (which results in reduced overall viral replication) but with tran-
sient/temporary increases (order of weeks) of common minority mutants can lead to
acceleration of rarer mutations appearance. Experimental data on the persistence
of small subpopulations of rare mutants, in unfavourable environments, should be
sought, as this aects the risk of subverting later regimens.
Simulations of the hybrid model shows that some unt drug resistant viruses,
even those carrying only a small tness cost relative to the wild-type strain, would
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not persist indenitely in the absence of selective pressure. This suggests that dis-
continuing failing therapy for a certain period may give patients a better opportunity
for viral suppression with subsequent regimens. The idea is to understand the eects
of suboptimal therapy and its interruption on patient management.
6.2 Future Directions
The topics discussed within this thesis leave considerable scope for further research
and development. Perhaps the most fruitful avenue would not be by developing more
nuanced or sophisticated mathematical models, but by working more closely with
specic data sets. For example, we constructed a model scenario inspired by data
about NVP containing regimens, by choosing a particular phylogeny to explore the
eects of a suboptimal regimen on the common and rare resistant mutants. It captures
the concepts of a primary, relatively unimpaired mutant, a number of unviable 2 base
mutants, and the possibility of compensatory mutations which lead to a treatment
defeating 3 base mutant that is reachable by dierent pathways which have dierent
relative importance at various stages during transient dynamics. While we do not
claim that this is a truly faithful representation of the relevant physiology, realistic
trees can be chosen, and they can be immediately accommodated into our general
framework. Recently, the advent of new sequencing technologies, vast amounts of
HIV-1 clinical data have become available for analysis. The mathematical modelling
presented in this thesis can be extended and coupled with statistical methods to
understand and predict the dynamics and control of HIV-1 infection.
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6.3 Strengthening Multidisciplinary Collaborations
In this thesis we have attempted to answer specic questions on viral evolution dur-
ing acute infection and suboptimal treatment using mathematical models. Perhaps
our models have generated more questions than answers, but these appear to be
important questions for the management of patients infected with HIV, so that vi-
ral evolution can be limited. The complex interplay between laboratory, clinical and
mathematical disciplines suggests that communication and active collaboration across
these elds should be enhanced, to develop new concepts in HIV/AIDS pathogenesis,
and understand their implications for patients.
Appendix A
Generating Functions
Generating functions are a useful tool for calculating probabilities and expectations.
Any sequence of real numbers can be transformed into several kinds of \generating
functions", in this case a power series. Let us consider a positive count (Z+) random
variable X, i.e. a discrete random variable taking non-negative values, such that
pk = P(X = k): We can write X  fpkgk0 and say that fpkg is the distribution of
X [75].
Denition A.0.1. (Denition of the probability generating function)[75]. The prob-
ability generating function GX of a Z+-valued random variable is a function GX(s) =
E(sX) =
P1
k=0 pks
k for those values of the parameter s for which the sum converges.
For a given sequence, there exists a radius of convergence such that the sum converges
absolutely if jsj < 1 and diverges if jsj > 1; i.e. the symbolic argument s 2 U  [0; 1]:
The following properties are true for the power series, GX(s) :
GX(1) = 1; and GX(0) = p0:
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We can recover the coecient pk by calculating the kth derivative of GX(s) at s = 0,
i.e
pk =
G
(k)
X (0)
k!
The kth factorial moment of X is k = G
(k)
X (1) such that the rst derivative of the
series evaluated at s = 1 is the expectation of the random variable X: If X and Y are
two independent Z+-valued random variables, then we have GX+Y (s) = GX(s)GY (s):
Proof.
GX+Y (s) = E(sX+Y );
= E(sX)E(sY ) (independence);
= GX(s)GY (s): (A.0.1)
If N is a discrete random variable with probability generating function GN : If
X1; X2;    ; XN are independent count random variables and identically distributed,
with a common probability generating function GX such that N;X1; X2;    ; XN are
independent count random variables, then SN = X1 +    + XN has a probability
generating function GSN (s) = GN(GX(s)) [52].
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Proof.
GSN (s) = E

sSN

=
1X
n=0
E

sSN
N = nP(N = n) (conditioning on N - see Appendix B)
=
1X
n=0
E(sSn)P(N = n)
=
1X
n=0
GX1++Xn(s)P(N = n)
=
1X
n=0
h
GX(s)
in
P(N = n)
= GN(GX(s)) (by denition of GN) (A.0.2)
This denition of the probability generating function can be generalized to the
multivariate case. Suppose that X = (X1;    ; Xn) 

pi1i2in
	
i1;i2; ;in0 is a nite
vector of non-negative random variables, or a Zn+-valued random variable.
Denition A.0.2. (Denition of the multivariate probability generating function)
[75]. The probability generating function GX of a Z
n
+-valued random variable X is
the function
GX(s) = E

sX11 s
X2
2    sXnn

=
1X
i1;i2; ;in0
pi1i2ins
i1
1 s
i2
2    sinn ; (A.0.3)
well dened if s = (s1; s2;    ; sn) 2 Un  [0; 1]n:
Theorem A.0.1. (Multivariate probability generating function theorem) [75]. Sup-
pose X is a Zn+-valued random variable with probability generating function GX
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1. GX is non-negative and continuous with all derivatives.
2. The marginal laws for subsets of Xi's can be obtained by setting respective ar-
guments of the probability generating function equal to 1, for example,
GX(s)jsj=1;j 6=i = GXi(si);
etc and GX(e) = 1; where e = (1;    ; 1):
3.
@k1++knGX(0)
@sk11    @sknn
= k1!    kn!pk1kn :
4.
k1; ;kn =
@k1++knGX(s)
@sk11    @sknn

s=e
:
5. If X and Y are two independent Zn+-valued random variables, then
GX+Y(s) = GX(s)GY(s):
6. If Y is a Zn+-valued random variable and
n
X
(i)
j ; i  1
o
; j = 1; 2;    ; n; are
sequences of Zm+ -valued random variables, then V =
Pn
j=1
PYj
ij=1
X
(ij)
j is a Z
m
+ -
valued random variable with probability generating function
GV(s) = GY
h
G
X
(1)
1
(s);    ; G
X
(1)
n
(s)
i
; s 2 Um:
Galton-Watson Branching Processes
In a Galton-Watson process, a population of individuals evolves in discrete time.
Each (n   1)st generation individual produces a random number of ospring in the
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nth generation. The state of the process at time n is the number of individuals in the
nth generation. For example, consider an organism that lives for exactly one time
unit and then dies in the process of giving birth to a family of similar organisms, C,
having the distribution P(C = k) = pk; k = 0; 1; 2;    [52].
If we let Pn be the number of individuals born at time n (i.e., the size of the nth
generation), the evolution of the population is described by the sequence of random
variables P0; P1; P2;    (an example of a stochastic process). We assume that P0 = 1,
i.e. we start with precisely one organism. Let g(s) be the probability generating
function of C (ospring) given by
g(s) =
1X
k=0
pks
k;
and Gn(s) the probability generating function of Pn given by
Gn(s) =
1X
x=0
P(Pn = x)sx:
Now we have G0(s) = s; since P(P0 = 1) = 1 and P(P0 = x) = 0 for x 6= 1: Also
G1(s) = g(s): The population size at generation n is
Pn =
Pn 1X
i=1
Ci;
that is, the number of individuals in the nth generation is equal to the number of
ospring of all individuals in the (n   1)st generation, where Ci is the size of the
family produced by the ith member of the (n 1)st generation. Any individual in the
nth generation of the process can be traced to its parent in the (n  1)st generation
of the process [52].
Now, since Pn is the sum of a random number of independent and identically
distributed (i.i.d.) random variables, we have
Gn(s) = Gn 1(g(s)) for n = 2; 3;    (A.0.4)
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Iterating equation A.0.4, we have
Gn(s) = Gn 1(g(s))
= g      g (n times) (A.0.5)
that is Gn is a composition (nth iterate) of g. For more general processes, equation
A.0.4 (also known as the forward equation) may not be feasible and for Galton-
Watson processes, the forward equation leads to the backward equation, i.e. Gn(s) =
g
 
Gn 1(s)

[75]. The single-type Galton-Watson branching process can also be gen-
eralized to the multi-type case.
The evolution of a population with multiple variants is a multi-type Galton-
Watson process (for further reference see [65, 75, 117]). In this process, each in-
dividual is assigned a type from a nite set T = f1;    ; rg; and each individual, say
of type i 2 T is associated with a random vector Ci = (Ci1;    ; Cir); where Cij is a
random variable that represents the number of ospring of type j born from a type
i individual. Given its type, the infected cell reproduces according to a probability
distribution. The probability that a type i parent cell produces k1 children of type 1,
k2 of type 2,   ; kr of type r is
pi(k1;    ; kr) = P

Ci = [k1;    ; kr]

; (A.0.6)
The ith generating function gi(s1;    ; sr) determines the distribution of the number
of ospring of various types to be produced by a type i cell
gi(s) = Ei

sk11    skrr

;
=
X
k1; ;kr
pi(k1;    ; kr)sk11    skrr ; js1j;    ; jsrj  1; (A.0.7)
such that
g(s) =

g1(s);    ; gr(s)

;
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where s = (s1;    ; sr): The multi-type GWBP is a vector-valued, non-negative ran-
dom process P(n) =

P1(n);    ; Pr(n)

; where Pi(n) represents the nth generation
size of type i with i = 1;    ; r: The vector forms a Markov chain describing the
population size and the type structure evolving generation-wise. In general, if
P(n  1) =

P1(n  1);    ; Pr(n  1)

;
then by summing the number of children generated by parent j of type i in generation
n  1; the vector-valued population size at generation n is given by
P(n) =
rX
i=1
Pi(n 1)X
j=1
C
(j)
i ;
where C
(j)
i is the ospring vector produced by each jth member of the ith type in
(n 1)st generation. Using the multivariate probability generating function theorem,
we have
Gn(s) = Gn 1(g(s)); (A.0.8)
the generating function of X(n); where G0(s) = s and G1(s) = g(s):
Appendix B
Conditional Expectation
See [52] for more details. If X and Y are discrete random variables with a joint
function dened by
pX;Y (x; y) = P(X = x; Y = y);
then the marginal probability mass function of X is
P(X = xi) =
X
y
P(X = xi; Y = y);
and that of Y is
P(Y = yi) =
X
x
P(X = x; Y = yi):
The conditional expected value of X given Y = yj is dened as:
E(XjY = yj) =
X
i
xiP(X = xijY = yj) (B.0.1)
=
X
i
xi
P(X = xi; Y = yj)
P (Y = yj)
; 8yj (j = 1; 2;    )
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Since E(XjY ) is a function of Y; we can write down its mean as
E[E(XjY )] =
X
j
E(XjY = yj)P(Y = yj)
=
X
j
X
i
xiP(X = xijY = yj)P(Y = yj) (from equation B.0.1)
=
X
j
X
i
xi
P(X = xi; Y = yj)
P(Y = yj)
P (Y = yj)
=
X
j
X
i
xiP(X = xi; Y = yj)
=
X
i
xi
X
j
P(X = xi; Y = yj)
=
X
i
xiP(X = xi) (marginal mass function of X)
= E(X) (B.0.2)
The result is very useful, it enables us to compute expectations easily by rst condi-
tioning on some random variable Y and using
E(X) =
X
j
E(XjY = yj)P(Y = yj): (B.0.3)
Appendix C
8-type Galton-Watson Branching
Process
The symmetric mutation matrix (M) for all the pathways is given by:
0BBBBBBBBBBBBBBBBBBBB@
P0 P1 P2 P3 P4 P5 P6 P7
P0 (1  )3 (1  )2 (1  )2 (1  )2 2(1  ) 2(1  ) 2(1  ) 3
P1 (1  )2 (1  )3 2(1  ) 2(1  ) (1  )2 3 (1  )2 2(1  )
P2 (1  )2 2(1  ) (1  )3 2(1  ) (1  )2 (1  )2 3 2(1  )
P3 (1  )2 2(1  ) 2(1  ) (1  )3 3 (1  )2 (1  )2 2(1  )
P4 
2(1  ) (1  )2 (1  )2 3 (1  )3 2(1  ) 2(1  ) (1  )2
P5 
2(1  ) 3 (1  )2 (1  )2 2(1  ) (1  )3 2(1  ) (1  )2
P6 
2(1  ) (1  )2 3 (1  )2 2(1  ) 2(1  ) (1  )3 (1  )2
P7 
3 2(1  ) 2(1  ) 2(1  ) (1  )2 (1  )2 (1  )2 (1  )3
1CCCCCCCCCCCCCCCCCCCCA
;
(C.0.1)
where the rows and columns are ordered as follows: wild-type strain (P0), three single-
point mutants (P1; P2; P3), three double-point mutants (P4; P5; P6) and a triple-point
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mutant (P7). The pgf of the wild-type ospring is given by:
gn0 (s0;    ; s7) = E

sk00    sk77

;
=
1X
k0=0
  
1X
k7=0

R0(n)
k0;    ; k7

(1  )3
k0   3k7sk00    sk77 ;
=
 7X
j=0
M(0; j)sj
R0(n)
;
(C.0.2)
where M(0; j) is the jth element (j = 0;    ; 7) of row 0 of matrix (C.0.1); our
indexing starts from zero and we have used the multinomial theorem to rewrite the
summation. Also the following sum is true,
P7
i=0 ki = R0(n); at every generation n:
Similarly, we can derive the ospring pgfs for all the mutants:
gn1 (s0;    ; s7) =
 7X
j=0
M(1; j)sj
R1(n)
   =   
gn7 (s0;    ; s7) =
 7X
j=0
M(7; j)sj
R7(n)
(C.0.3)
where Ri(n); i = 0;    ; 7 is strain i eective reproductive number function such that
gn(s) =

gn0 (s);    ; gn7 (s)

; (C.0.4)
where s = (s0;    ; s7): We assume that the infection process is started from a single
wild-type infected cell, i.e. fP0(0) = 1; P1(0) = 0;    ; P7(0) = 0g: We can use the
iteration
Gni (s) = G
n 1
i

gn0 (s);    ; gn7 (s)

; n = 2; 3;    (C.0.5)
to derive the pgfs for the distribution law of the number of cells at every generation.
Appendix D
Mutation Combinatorics
We relate the HIV mutation process parameters ij and f to an underlying single-
point-mutation process. The error rate per site for HIV reverse transcriptase (for any
given nucleotide A, C, G and T) is assumed to be 10 4 [109], so that the rate of change
to any of the three alternatives (for example substitution of A by C, G or T) is given
by  = 1
3
 10 4: The probability that a site within a gene will remain unchanged
after reverse transcription (i.e. A ! A, C ! C, T ! T or G ! G) is given by
(1  3): Then the probability of a particular mutation (strain j ! strain i); where i
and j dier by precisely m point mutations, given a genome length L (approximately
104 bases for HIV) is given by
ij = (1  3)L mm  (1  3)Lm  fm; (D.0.1)
where m << L and 1  3  1: Note that f = (1  3)L  0:37 is the probability of
error free replication. For example, we consider particular point mutations at codon
103 of reverse trancriptase gene that are associated with 103K/N viral populations.
Given that AAA & AAG code for K and AAC & AAT code for N, the rate of lysine
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(K) substitutions by asparagine (N) at this codon is given by
P(K! N) = 2f: (D.0.2)
The single point mutation rate at this codon using equation D.0.2 is given by 21 =
2:5  10 5: Then, using equation D.0.1, we have 31 = f3  1:4  10 14 and 32 =
f2  4:1 10 10:
Appendix E
The Direct Hybrid Method
To simulate our system (with the phylogeny given in chapter 4), we use the direct
hybrid method [2]:
1. Initialize the system T (0); P1(0); P2(0); P3(0); L1(0); L2(0); L3(0) and set the ini-
tial time t = t0;
2. Generate a random variable   Exp(1);
3. Set g(t=t) = 0 and solve the system of ODEs starting at time  = t
dT ()
d
= ST   T ()
2X
i=1
kiPi()  TT ()
dPi()
d
= fFkiPi()T () + T ()
2X
j=1
j 6=i
ijkjPj() + aLi()  PPi(); i = 1; 2
dLi()
d
= f(1  F )kiPi()T ()  aLi(); i = 1; 2
g(=t)
d
= fk3P3()T () + T ()
2X
i=1
3ikiPi() + aL3() + PP3() (E.0.1)
until time  = s such that g(s=t) = ;
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4. Generate a discrete random variable with values in D and probabilities (Table
5.2) in order to determine the event to be performed.
5. Make the indicated jump, update the time to t = s and go to step 2.
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